[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"$fQrPbiZ7QDjW1jQ4uaxyLKLDZHCPMstBmn0TOHl8A6Qw":3},{"sponsor":4,"sponsorVariants":5,"totalTrials":6,"truncated":7,"activeTrials":8,"phase3Count":9,"totalEnrollment":10,"activePrograms":11,"nonDrugCount":12,"topConditions":13,"upcomingReadouts":35,"phaseBuckets":84,"rows":91},"Cedars-Sinai Medical Center",[4],445,false,117,14,83674,52,299,[14,17,20,23,25,27,29,32],{"name":15,"count":16},"Breast Cancer",13,{"name":18,"count":19},"Coronary Artery Disease",12,{"name":21,"count":22},"Depression",10,{"name":24,"count":22},"Cancer",{"name":26,"count":22},"Prostate Cancer",{"name":28,"count":22},"Hypertension",{"name":30,"count":31},"Acromegaly",9,{"name":33,"count":34},"Pain",7,[36,41,46,51,56,61,66,70,75,79],{"nctId":37,"briefTitle":38,"date":39,"intervention":40},"NCT04386317","Terazosin Effect on Cardiac Changes in Early Parkinson's Disease","2025-12-10","Terazosin",{"nctId":42,"briefTitle":43,"date":44,"intervention":45},"NCT03504956","Coronary Atherosclerosis T1-Weighted Characterization (CATCH)","2025-12-31","Contrast",{"nctId":47,"briefTitle":48,"date":49,"intervention":50},"NCT05109364","Terazosin and Parkinson's Disease Extension Study","2026-03-10","Terazosin therapy",{"nctId":52,"briefTitle":53,"date":54,"intervention":55},"NCT03292861","The Effect and Safety Profile of Thymoglobulin® in Primary Cardiac Transplant Recipients","2026-03-31","Thymoglobulin",{"nctId":57,"briefTitle":58,"date":59,"intervention":60},"NCT05664880","A PiLot ClinicaL TrIal of ParicAlcitol for ChroNiC PancrEatitis","2026-06-01","Paricalcitol",{"nctId":62,"briefTitle":63,"date":64,"intervention":65},"NCT04218968","Cardiac Changes in Early Parkinson's Disease: A Follow up Study","2026-06-30","Carvedilol",{"nctId":67,"briefTitle":68,"date":64,"intervention":69},"NCT05515627","Atezolizumab for Idiopathic Pulmonary Fibrosis","Atezolizumab",{"nctId":71,"briefTitle":72,"date":73,"intervention":74},"NCT04284293","CNS10-NPC for the Treatment of RP","2026-07","CNS10-NPC implantation",{"nctId":76,"briefTitle":77,"date":73,"intervention":78},"NCT07400146","Bupivacaine With Epinephrine Over Diaphragm in Laparoscopy","Instillation of Bupivacaine with epinephrine over the diaphragm",{"nctId":80,"briefTitle":81,"date":82,"intervention":83},"NCT05086250","Feasibility Study of Oral Ketamine Versus Placebo for the Treatment of Anxiety in Patients With Pancreatic Cancer","2026-07-15","Ketamine",[85,86,87,88,89,90],"EARLY_PHASE1","PHASE1","PHASE2","PHASE3","PHASE4","NA",[92,118,143,170,188,206,235,284,312,330,363,399,454,472,490,508,526,544,562,587,609,632,652,678,712,730,748,766,784,802,820,838,856,874,892,917,935,961,979,998,1024,1049,1070,1094,1115,1157,1189,1214,1238,1270,1294,1312,1330,1386,1429,1479,1514,1536,1568,1596,1631,1654,1679,1703,1728,1746,1764,1782,1808,1832,1850,1876,1894,1921,1939,1966,1984,2002,2020,2045,2077,2095,2119,2145,2163,2189,2214,2232,2250,2268,2286,2312,2339,2357,2375,2399,2423,2448,2494,2518,2542,2568,2586,2616,2634,2652,2670,2726,2763,2789,2807,2825,2850,2874,2899,2924,2942,2960,2986,3011,3029,3047,3075,3107,3131,3149,3167,3191,3216,3234,3263,3281,3299,3326,3344,3369,3392,3419,3450,3468,3486,3509,3533,3560,3586,3610,3636,3659,3681,3709,3727,3745,3772,3798,3821,3846,3864,3882,3900,3924,3950,3974,3998,4025,4047,4074,4092,4115,4138,4156,4174,4201,4219,4237,4271,4298,4329,4352,4375,4393,4417,4443,4461,4479,4497,4520,4538,4564,4582,4606,4630,4648,4670,4688,4711,4737,4765,4783],{"intervention":78,"totalTrials":93,"cells":94},1,{"EARLY_PHASE1":95,"PHASE1":98,"PHASE2":100,"PHASE3":102,"PHASE4":104,"NA":116},{"trials":96,"activeCount":97},[],0,{"trials":99,"activeCount":97},[],{"trials":101,"activeCount":97},[],{"trials":103,"activeCount":97},[],{"trials":105,"activeCount":93,"soonestReadout":73},[106],{"nctId":76,"briefTitle":77,"status":107,"phases":108,"primaryCompletion":73,"completion":109,"start":110,"enrollment":111,"conditions":112,"interventions":115},"NOT_YET_RECRUITING",[89],"2026-08","2026-02",100,[113,114],"Postoperative Pain","Shoulder Pain",[78],{"trials":117,"activeCount":97},[],{"intervention":119,"totalTrials":93,"cells":120},"Bupivacaine liposome injectable suspension",{"EARLY_PHASE1":121,"PHASE1":123,"PHASE2":125,"PHASE3":127,"PHASE4":129,"NA":141},{"trials":122,"activeCount":97},[],{"trials":124,"activeCount":97},[],{"trials":126,"activeCount":97},[],{"trials":128,"activeCount":97},[],{"trials":130,"activeCount":93,"soonestReadout":109},[131],{"nctId":132,"briefTitle":133,"status":134,"phases":135,"primaryCompletion":109,"completion":109,"start":59,"enrollment":136,"conditions":137,"interventions":140},"NCT07584915","Pilot Study on EXPAREL as an Intra-articular Posteromedial Surgeon Administered (IPSA) Block vs. Local Infiltration Analgesia in Knee Replacement Surgery","ENROLLING_BY_INVITATION",[89],40,[138,139],"Total Knee Arthroplasty","Total Knee Arthroplasty Recovery",[119,119],{"trials":142,"activeCount":97},[],{"intervention":144,"totalTrials":93,"cells":145},"High dose potent statin",{"EARLY_PHASE1":146,"PHASE1":148,"PHASE2":150,"PHASE3":152,"PHASE4":154,"NA":168},{"trials":147,"activeCount":97},[],{"trials":149,"activeCount":97},[],{"trials":151,"activeCount":97},[],{"trials":153,"activeCount":97},[],{"trials":155,"activeCount":93,"soonestReadout":161},[156],{"nctId":157,"briefTitle":158,"status":159,"phases":160,"primaryCompletion":161,"completion":161,"start":162,"enrollment":163,"conditions":164,"interventions":165},"NCT03417388","Women's IschemiA TRial to Reduce Events In Non-ObstRuctive CAD","ACTIVE_NOT_RECRUITING",[89],"2026-09-14","2018-02-09",2476,[18],[144,166,167],"ACE-I","Aspirin 81 enteric coated tablet daily",{"trials":169,"activeCount":97},[],{"intervention":166,"totalTrials":93,"cells":171},{"EARLY_PHASE1":172,"PHASE1":174,"PHASE2":176,"PHASE3":178,"PHASE4":180,"NA":186},{"trials":173,"activeCount":97},[],{"trials":175,"activeCount":97},[],{"trials":177,"activeCount":97},[],{"trials":179,"activeCount":97},[],{"trials":181,"activeCount":93,"soonestReadout":161},[182],{"nctId":157,"briefTitle":158,"status":159,"phases":183,"primaryCompletion":161,"completion":161,"start":162,"enrollment":163,"conditions":184,"interventions":185},[89],[18],[144,166,167],{"trials":187,"activeCount":97},[],{"intervention":167,"totalTrials":93,"cells":189},{"EARLY_PHASE1":190,"PHASE1":192,"PHASE2":194,"PHASE3":196,"PHASE4":198,"NA":204},{"trials":191,"activeCount":97},[],{"trials":193,"activeCount":97},[],{"trials":195,"activeCount":97},[],{"trials":197,"activeCount":97},[],{"trials":199,"activeCount":93,"soonestReadout":161},[200],{"nctId":157,"briefTitle":158,"status":159,"phases":201,"primaryCompletion":161,"completion":161,"start":162,"enrollment":163,"conditions":202,"interventions":203},[89],[18],[144,166,167],{"trials":205,"activeCount":97},[],{"intervention":207,"totalTrials":93,"cells":208},"CYTALUX™",{"EARLY_PHASE1":209,"PHASE1":211,"PHASE2":213,"PHASE3":215,"PHASE4":217,"NA":233},{"trials":210,"activeCount":97},[],{"trials":212,"activeCount":97},[],{"trials":214,"activeCount":97},[],{"trials":216,"activeCount":97},[],{"trials":218,"activeCount":93,"soonestReadout":109},[219],{"nctId":220,"briefTitle":221,"status":222,"phases":223,"primaryCompletion":109,"completion":224,"start":225,"enrollment":226,"conditions":227,"interventions":232},"NCT07124351","Intraoperative Imaging of Gastrointestinal Malignancies Using Pafolacianine (CYTALUX™)","RECRUITING",[89],"2026-09","2025-09-05",15,[228,229,230,231],"Gastrointestinal Cancer","Gastric Cancer","Esophageal Cancer","Appendiceal Cancer",[207],{"trials":234,"activeCount":97},[],{"intervention":236,"totalTrials":237,"cells":238},"Bupivacaine",3,{"EARLY_PHASE1":239,"PHASE1":241,"PHASE2":243,"PHASE3":245,"PHASE4":257,"NA":259},{"trials":240,"activeCount":97},[],{"trials":242,"activeCount":97},[],{"trials":244,"activeCount":97},[],{"trials":246,"activeCount":93,"soonestReadout":251},[247],{"nctId":248,"briefTitle":249,"status":222,"phases":250,"primaryCompletion":251,"completion":251,"start":252,"enrollment":253,"conditions":254,"interventions":256},"NCT04979338","Development of Effective, Opioid Sparing Techniques for Peri-operative Pain Management of Transgender Patients Undergoing Gender Affirming Surgeries",[88],"2026-09-30","2021-11-11",640,[255],"Gender Dysphoria",[236],{"trials":258,"activeCount":97},[],{"trials":260,"activeCount":93,"soonestReadout":277},[261,273],{"nctId":262,"briefTitle":263,"status":264,"phases":265,"primaryCompletion":266,"completion":266,"start":267,"enrollment":268,"conditions":269,"interventions":271},"NCT02669186","Effects of Anesthetic Technique on NK Cells","UNKNOWN",[90],"2025-12","2019-07-10",20,[33,270,24],"Anesthesia",[272,236],"Bupivacaine + Fentanyl",{"nctId":274,"briefTitle":275,"status":222,"phases":276,"primaryCompletion":277,"completion":277,"start":278,"enrollment":279,"conditions":280,"interventions":282},"NCT06338865","Short Title: Standard vs. Lower Pressure Pneumoperitoneum",[90],"2027-04","2024-05-03",294,[281],"Laparoscopic Surgery",[236,283],"Oxycodone",{"intervention":285,"totalTrials":93,"cells":286},"Dasatinib 100 MG",{"EARLY_PHASE1":287,"PHASE1":289,"PHASE2":291,"PHASE3":293,"PHASE4":308,"NA":310},{"trials":288,"activeCount":97},[],{"trials":290,"activeCount":97},[],{"trials":292,"activeCount":97},[],{"trials":294,"activeCount":93,"soonestReadout":299},[295],{"nctId":296,"briefTitle":297,"status":222,"phases":298,"primaryCompletion":299,"completion":300,"start":301,"enrollment":302,"conditions":303,"interventions":306},"NCT05653258","Single Nuclei RNA-seq to Map Adipose Cellular Populations and Senescent Cells in Older Subjects",[87,88],"2027-02-01","2028-02-01","2023-10-17",160,[304,305],"Obesity","Healthy Lifestyle",[285,307],"Quercetin 1000mg",{"trials":309,"activeCount":97},[],{"trials":311,"activeCount":97},[],{"intervention":307,"totalTrials":93,"cells":313},{"EARLY_PHASE1":314,"PHASE1":316,"PHASE2":318,"PHASE3":320,"PHASE4":326,"NA":328},{"trials":315,"activeCount":97},[],{"trials":317,"activeCount":97},[],{"trials":319,"activeCount":97},[],{"trials":321,"activeCount":93,"soonestReadout":299},[322],{"nctId":296,"briefTitle":297,"status":222,"phases":323,"primaryCompletion":299,"completion":300,"start":301,"enrollment":302,"conditions":324,"interventions":325},[87,88],[304,305],[285,307],{"trials":327,"activeCount":97},[],{"trials":329,"activeCount":97},[],{"intervention":331,"totalTrials":332,"cells":333},"Mirabegron",2,{"EARLY_PHASE1":334,"PHASE1":336,"PHASE2":338,"PHASE3":357,"PHASE4":359,"NA":361},{"trials":335,"activeCount":97},[],{"trials":337,"activeCount":97},[],{"trials":339,"activeCount":332,"soonestReadout":344},[340,349],{"nctId":341,"briefTitle":342,"status":107,"phases":343,"primaryCompletion":344,"completion":344,"start":345,"enrollment":268,"conditions":346,"interventions":348},"NCT07566208","Using Mirabegron to Control Arrhythmia-1",[87],"2028-05","2026-05",[347],"Ventricular Arrhythmias and Cardiac Arrest",[331],{"nctId":350,"briefTitle":351,"status":107,"phases":352,"primaryCompletion":344,"completion":344,"start":345,"enrollment":353,"conditions":354,"interventions":356},"NCT07585513","Beta-3 Enhanced Autonomic Therapy for POTS",[87],36,[355],"Postural Orthostatic Tachycardia Syndrome (POTS)",[331],{"trials":358,"activeCount":97},[],{"trials":360,"activeCount":97},[],{"trials":362,"activeCount":97},[],{"intervention":55,"totalTrials":332,"cells":364},{"EARLY_PHASE1":365,"PHASE1":367,"PHASE2":369,"PHASE3":382,"PHASE4":395,"NA":397},{"trials":366,"activeCount":97},[],{"trials":368,"activeCount":97},[],{"trials":370,"activeCount":93,"soonestReadout":54},[371],{"nctId":52,"briefTitle":53,"status":134,"phases":372,"primaryCompletion":54,"completion":54,"start":373,"enrollment":374,"conditions":375,"interventions":377},[87],"2018-09-13",60,[376],"Heart Transplantation",[55,378,379,380,381],"Mycophenolate Mofetil","Tacrolimus","Sirolimus","Corticosteroids",{"trials":383,"activeCount":97},[384],{"nctId":385,"briefTitle":386,"status":387,"phases":388,"primaryCompletion":389,"completion":390,"start":391,"enrollment":97,"conditions":392,"interventions":394},"NCT01157949","A Study to Compare the Effectiveness of a Drug That Suppresses the Immune System Called Thymoglobulin® in Preventing the Development of a Disease That Affects the Majority of Heart Transplant Recipients Called Cardiac Allograft Vasculopathy (CAV)","WITHDRAWN",[88],"2013-11","2018-01-10","2010-11",[393],"Cardiac Allograft Vasculopathy",[55],{"trials":396,"activeCount":97},[],{"trials":398,"activeCount":97},[],{"intervention":400,"totalTrials":237,"cells":401},"Carboplatin",{"EARLY_PHASE1":402,"PHASE1":418,"PHASE2":420,"PHASE3":448,"PHASE4":450,"NA":452},{"trials":403,"activeCount":97},[404],{"nctId":405,"briefTitle":406,"status":407,"phases":408,"primaryCompletion":409,"completion":410,"start":411,"enrollment":34,"conditions":412,"interventions":416},"NCT02279992","Pilot Study of Vardenafil and Carboplatin in Patients With Gliomas and Brain Metastases","TERMINATED",[85],"2013-10-13","2016-02-11","2012-03-27",[413,414,415],"Glioma","Brain Neoplasms","Brain Metastasis",[417,400],"Vardenafil",{"trials":419,"activeCount":97},[],{"trials":421,"activeCount":93,"soonestReadout":426},[422,437],{"nctId":423,"briefTitle":424,"status":222,"phases":425,"primaryCompletion":426,"completion":427,"start":428,"enrollment":429,"conditions":430,"interventions":434},"NCT07017673","Phase II Trial of Ivonescimab in Combination With Carboplatin + Docetaxel in Patients With Early-Stage Triple Negative Breast Cancer",[87],"2027-12","2032-11","2025-07-25",34,[431,432,433],"TNBC","TNBC - Triple-Negative Breast Cancer","Early Stage Triple-Negative Breast Carcinoma",[435,400,436],"Ivonescimab","Docetaxel",{"nctId":438,"briefTitle":439,"status":387,"phases":440,"primaryCompletion":441,"completion":442,"start":441,"enrollment":97,"conditions":443,"interventions":445},"NCT03872505","Pre-operAtive Non-Anthracycline Chemotherapy, Durvalumab +\u002F- RAdiation Therapy in Triple Negative Breast Cancer",[87],"2022-07","2027-07",[15,444],"Triple Negative Breast Cancer",[446,400,447],"Durvalumab","Paclitaxel",{"trials":449,"activeCount":97},[],{"trials":451,"activeCount":97},[],{"trials":453,"activeCount":97},[],{"intervention":378,"totalTrials":93,"cells":455},{"EARLY_PHASE1":456,"PHASE1":458,"PHASE2":460,"PHASE3":466,"PHASE4":468,"NA":470},{"trials":457,"activeCount":97},[],{"trials":459,"activeCount":97},[],{"trials":461,"activeCount":93,"soonestReadout":54},[462],{"nctId":52,"briefTitle":53,"status":134,"phases":463,"primaryCompletion":54,"completion":54,"start":373,"enrollment":374,"conditions":464,"interventions":465},[87],[376],[55,378,379,380,381],{"trials":467,"activeCount":97},[],{"trials":469,"activeCount":97},[],{"trials":471,"activeCount":97},[],{"intervention":379,"totalTrials":93,"cells":473},{"EARLY_PHASE1":474,"PHASE1":476,"PHASE2":478,"PHASE3":484,"PHASE4":486,"NA":488},{"trials":475,"activeCount":97},[],{"trials":477,"activeCount":97},[],{"trials":479,"activeCount":93,"soonestReadout":54},[480],{"nctId":52,"briefTitle":53,"status":134,"phases":481,"primaryCompletion":54,"completion":54,"start":373,"enrollment":374,"conditions":482,"interventions":483},[87],[376],[55,378,379,380,381],{"trials":485,"activeCount":97},[],{"trials":487,"activeCount":97},[],{"trials":489,"activeCount":97},[],{"intervention":380,"totalTrials":93,"cells":491},{"EARLY_PHASE1":492,"PHASE1":494,"PHASE2":496,"PHASE3":502,"PHASE4":504,"NA":506},{"trials":493,"activeCount":97},[],{"trials":495,"activeCount":97},[],{"trials":497,"activeCount":93,"soonestReadout":54},[498],{"nctId":52,"briefTitle":53,"status":134,"phases":499,"primaryCompletion":54,"completion":54,"start":373,"enrollment":374,"conditions":500,"interventions":501},[87],[376],[55,378,379,380,381],{"trials":503,"activeCount":97},[],{"trials":505,"activeCount":97},[],{"trials":507,"activeCount":97},[],{"intervention":381,"totalTrials":93,"cells":509},{"EARLY_PHASE1":510,"PHASE1":512,"PHASE2":514,"PHASE3":520,"PHASE4":522,"NA":524},{"trials":511,"activeCount":97},[],{"trials":513,"activeCount":97},[],{"trials":515,"activeCount":93,"soonestReadout":54},[516],{"nctId":52,"briefTitle":53,"status":134,"phases":517,"primaryCompletion":54,"completion":54,"start":373,"enrollment":374,"conditions":518,"interventions":519},[87],[376],[55,378,379,380,381],{"trials":521,"activeCount":97},[],{"trials":523,"activeCount":97},[],{"trials":525,"activeCount":97},[],{"intervention":435,"totalTrials":93,"cells":527},{"EARLY_PHASE1":528,"PHASE1":530,"PHASE2":532,"PHASE3":538,"PHASE4":540,"NA":542},{"trials":529,"activeCount":97},[],{"trials":531,"activeCount":97},[],{"trials":533,"activeCount":93,"soonestReadout":426},[534],{"nctId":423,"briefTitle":424,"status":222,"phases":535,"primaryCompletion":426,"completion":427,"start":428,"enrollment":429,"conditions":536,"interventions":537},[87],[431,432,433],[435,400,436],{"trials":539,"activeCount":97},[],{"trials":541,"activeCount":97},[],{"trials":543,"activeCount":97},[],{"intervention":436,"totalTrials":93,"cells":545},{"EARLY_PHASE1":546,"PHASE1":548,"PHASE2":550,"PHASE3":556,"PHASE4":558,"NA":560},{"trials":547,"activeCount":97},[],{"trials":549,"activeCount":97},[],{"trials":551,"activeCount":93,"soonestReadout":426},[552],{"nctId":423,"briefTitle":424,"status":222,"phases":553,"primaryCompletion":426,"completion":427,"start":428,"enrollment":429,"conditions":554,"interventions":555},[87],[431,432,433],[435,400,436],{"trials":557,"activeCount":97},[],{"trials":559,"activeCount":97},[],{"trials":561,"activeCount":97},[],{"intervention":563,"totalTrials":93,"cells":564},"Cisplatin Chemotherapy",{"EARLY_PHASE1":565,"PHASE1":567,"PHASE2":569,"PHASE3":581,"PHASE4":583,"NA":585},{"trials":566,"activeCount":97},[],{"trials":568,"activeCount":97},[],{"trials":570,"activeCount":93,"soonestReadout":575},[571],{"nctId":572,"briefTitle":573,"status":159,"phases":574,"primaryCompletion":575,"completion":576,"start":577,"enrollment":136,"conditions":578,"interventions":580},"NCT04502407","Trial of De-Intensified Post-operative Chemoradiation Following Robotic Surgery for HPV-positive Oropharyngeal Cancer",[87],"2026-12-15","2029-12-15","2021-02-16",[579],"HPV Positive Oropharyngeal Squamous Cell Carcinoma",[563],{"trials":582,"activeCount":97},[],{"trials":584,"activeCount":97},[],{"trials":586,"activeCount":97},[],{"intervention":65,"totalTrials":93,"cells":588},{"EARLY_PHASE1":589,"PHASE1":591,"PHASE2":593,"PHASE3":603,"PHASE4":605,"NA":607},{"trials":590,"activeCount":97},[],{"trials":592,"activeCount":97},[],{"trials":594,"activeCount":93,"soonestReadout":64},[595],{"nctId":62,"briefTitle":63,"status":159,"phases":596,"primaryCompletion":64,"completion":64,"start":597,"enrollment":226,"conditions":598,"interventions":602},[87],"2019-12-30",[599,600,601],"REM Sleep Behavior Disorder","Pre-motor Parkinson Disease","Symptomatic Parkinson Disease",[65],{"trials":604,"activeCount":97},[],{"trials":606,"activeCount":97},[],{"trials":608,"activeCount":97},[],{"intervention":610,"totalTrials":93,"cells":611},"Seliciclib",{"EARLY_PHASE1":612,"PHASE1":614,"PHASE2":616,"PHASE3":626,"PHASE4":628,"NA":630},{"trials":613,"activeCount":97},[],{"trials":615,"activeCount":97},[],{"trials":617,"activeCount":93,"soonestReadout":109},[618],{"nctId":619,"briefTitle":620,"status":222,"phases":621,"primaryCompletion":109,"completion":109,"start":622,"enrollment":16,"conditions":623,"interventions":625},"NCT03774446","Multicenter Study of Seliciclib (R-roscovitine) for Cushing Disease",[87],"2018-11-02",[624],"Cushing Disease",[610],{"trials":627,"activeCount":97},[],{"trials":629,"activeCount":97},[],{"trials":631,"activeCount":97},[],{"intervention":40,"totalTrials":93,"cells":633},{"EARLY_PHASE1":634,"PHASE1":636,"PHASE2":638,"PHASE3":646,"PHASE4":648,"NA":650},{"trials":635,"activeCount":97},[],{"trials":637,"activeCount":97},[],{"trials":639,"activeCount":93,"soonestReadout":39},[640],{"nctId":37,"briefTitle":38,"status":159,"phases":641,"primaryCompletion":39,"completion":49,"start":642,"enrollment":226,"conditions":643,"interventions":645},[87],"2020-11-01",[599,644,601],"Pre-motor Parkinson's Disease",[40],{"trials":647,"activeCount":97},[],{"trials":649,"activeCount":97},[],{"trials":651,"activeCount":97},[],{"intervention":653,"totalTrials":93,"cells":654},"S-adenosyl-L-methionine",{"EARLY_PHASE1":655,"PHASE1":657,"PHASE2":659,"PHASE3":672,"PHASE4":674,"NA":676},{"trials":656,"activeCount":97},[],{"trials":658,"activeCount":97},[],{"trials":660,"activeCount":93,"soonestReadout":665},[661],{"nctId":662,"briefTitle":663,"status":107,"phases":664,"primaryCompletion":665,"completion":666,"start":667,"enrollment":668,"conditions":669,"interventions":671},"NCT07495995","SAMe for Prevention of Liver Cancer in MASLD-Related Cirrhosis",[87],"2030-12-31","2031-12-31","2026-04-15",94,[670],"Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD)",[653],{"trials":673,"activeCount":97},[],{"trials":675,"activeCount":97},[],{"trials":677,"activeCount":97},[],{"intervention":679,"totalTrials":93,"cells":680},"Mesna",{"EARLY_PHASE1":681,"PHASE1":683,"PHASE2":685,"PHASE3":706,"PHASE4":708,"NA":710},{"trials":682,"activeCount":97},[],{"trials":684,"activeCount":97},[],{"trials":686,"activeCount":93,"soonestReadout":691},[687],{"nctId":688,"briefTitle":689,"status":222,"phases":690,"primaryCompletion":691,"completion":691,"start":692,"enrollment":226,"conditions":693,"interventions":695},"NCT04224558","Stem Cell Transplantation in Crohn's Disease",[86,87],"2027-09-30","2019-11-15",[694],"Crohn Disease",[679,696,697,698,699,700,701,702,703,704,705],"Cyclophosphamide","Filgrastim","Fludarabine","Methylprednisolone","Diphenhydramine","Acetaminophen","anti-thymocyte globulin","lymphocyte immune globulin","Peripheral Blood Stem Cell","Cytoxan",{"trials":707,"activeCount":97},[],{"trials":709,"activeCount":97},[],{"trials":711,"activeCount":97},[],{"intervention":696,"totalTrials":93,"cells":713},{"EARLY_PHASE1":714,"PHASE1":716,"PHASE2":718,"PHASE3":724,"PHASE4":726,"NA":728},{"trials":715,"activeCount":97},[],{"trials":717,"activeCount":97},[],{"trials":719,"activeCount":93,"soonestReadout":691},[720],{"nctId":688,"briefTitle":689,"status":222,"phases":721,"primaryCompletion":691,"completion":691,"start":692,"enrollment":226,"conditions":722,"interventions":723},[86,87],[694],[679,696,697,698,699,700,701,702,703,704,705],{"trials":725,"activeCount":97},[],{"trials":727,"activeCount":97},[],{"trials":729,"activeCount":97},[],{"intervention":697,"totalTrials":93,"cells":731},{"EARLY_PHASE1":732,"PHASE1":734,"PHASE2":736,"PHASE3":742,"PHASE4":744,"NA":746},{"trials":733,"activeCount":97},[],{"trials":735,"activeCount":97},[],{"trials":737,"activeCount":93,"soonestReadout":691},[738],{"nctId":688,"briefTitle":689,"status":222,"phases":739,"primaryCompletion":691,"completion":691,"start":692,"enrollment":226,"conditions":740,"interventions":741},[86,87],[694],[679,696,697,698,699,700,701,702,703,704,705],{"trials":743,"activeCount":97},[],{"trials":745,"activeCount":97},[],{"trials":747,"activeCount":97},[],{"intervention":698,"totalTrials":93,"cells":749},{"EARLY_PHASE1":750,"PHASE1":752,"PHASE2":754,"PHASE3":760,"PHASE4":762,"NA":764},{"trials":751,"activeCount":97},[],{"trials":753,"activeCount":97},[],{"trials":755,"activeCount":93,"soonestReadout":691},[756],{"nctId":688,"briefTitle":689,"status":222,"phases":757,"primaryCompletion":691,"completion":691,"start":692,"enrollment":226,"conditions":758,"interventions":759},[86,87],[694],[679,696,697,698,699,700,701,702,703,704,705],{"trials":761,"activeCount":97},[],{"trials":763,"activeCount":97},[],{"trials":765,"activeCount":97},[],{"intervention":699,"totalTrials":93,"cells":767},{"EARLY_PHASE1":768,"PHASE1":770,"PHASE2":772,"PHASE3":778,"PHASE4":780,"NA":782},{"trials":769,"activeCount":97},[],{"trials":771,"activeCount":97},[],{"trials":773,"activeCount":93,"soonestReadout":691},[774],{"nctId":688,"briefTitle":689,"status":222,"phases":775,"primaryCompletion":691,"completion":691,"start":692,"enrollment":226,"conditions":776,"interventions":777},[86,87],[694],[679,696,697,698,699,700,701,702,703,704,705],{"trials":779,"activeCount":97},[],{"trials":781,"activeCount":97},[],{"trials":783,"activeCount":97},[],{"intervention":700,"totalTrials":93,"cells":785},{"EARLY_PHASE1":786,"PHASE1":788,"PHASE2":790,"PHASE3":796,"PHASE4":798,"NA":800},{"trials":787,"activeCount":97},[],{"trials":789,"activeCount":97},[],{"trials":791,"activeCount":93,"soonestReadout":691},[792],{"nctId":688,"briefTitle":689,"status":222,"phases":793,"primaryCompletion":691,"completion":691,"start":692,"enrollment":226,"conditions":794,"interventions":795},[86,87],[694],[679,696,697,698,699,700,701,702,703,704,705],{"trials":797,"activeCount":97},[],{"trials":799,"activeCount":97},[],{"trials":801,"activeCount":97},[],{"intervention":701,"totalTrials":93,"cells":803},{"EARLY_PHASE1":804,"PHASE1":806,"PHASE2":808,"PHASE3":814,"PHASE4":816,"NA":818},{"trials":805,"activeCount":97},[],{"trials":807,"activeCount":97},[],{"trials":809,"activeCount":93,"soonestReadout":691},[810],{"nctId":688,"briefTitle":689,"status":222,"phases":811,"primaryCompletion":691,"completion":691,"start":692,"enrollment":226,"conditions":812,"interventions":813},[86,87],[694],[679,696,697,698,699,700,701,702,703,704,705],{"trials":815,"activeCount":97},[],{"trials":817,"activeCount":97},[],{"trials":819,"activeCount":97},[],{"intervention":702,"totalTrials":93,"cells":821},{"EARLY_PHASE1":822,"PHASE1":824,"PHASE2":826,"PHASE3":832,"PHASE4":834,"NA":836},{"trials":823,"activeCount":97},[],{"trials":825,"activeCount":97},[],{"trials":827,"activeCount":93,"soonestReadout":691},[828],{"nctId":688,"briefTitle":689,"status":222,"phases":829,"primaryCompletion":691,"completion":691,"start":692,"enrollment":226,"conditions":830,"interventions":831},[86,87],[694],[679,696,697,698,699,700,701,702,703,704,705],{"trials":833,"activeCount":97},[],{"trials":835,"activeCount":97},[],{"trials":837,"activeCount":97},[],{"intervention":703,"totalTrials":93,"cells":839},{"EARLY_PHASE1":840,"PHASE1":842,"PHASE2":844,"PHASE3":850,"PHASE4":852,"NA":854},{"trials":841,"activeCount":97},[],{"trials":843,"activeCount":97},[],{"trials":845,"activeCount":93,"soonestReadout":691},[846],{"nctId":688,"briefTitle":689,"status":222,"phases":847,"primaryCompletion":691,"completion":691,"start":692,"enrollment":226,"conditions":848,"interventions":849},[86,87],[694],[679,696,697,698,699,700,701,702,703,704,705],{"trials":851,"activeCount":97},[],{"trials":853,"activeCount":97},[],{"trials":855,"activeCount":97},[],{"intervention":704,"totalTrials":93,"cells":857},{"EARLY_PHASE1":858,"PHASE1":860,"PHASE2":862,"PHASE3":868,"PHASE4":870,"NA":872},{"trials":859,"activeCount":97},[],{"trials":861,"activeCount":97},[],{"trials":863,"activeCount":93,"soonestReadout":691},[864],{"nctId":688,"briefTitle":689,"status":222,"phases":865,"primaryCompletion":691,"completion":691,"start":692,"enrollment":226,"conditions":866,"interventions":867},[86,87],[694],[679,696,697,698,699,700,701,702,703,704,705],{"trials":869,"activeCount":97},[],{"trials":871,"activeCount":97},[],{"trials":873,"activeCount":97},[],{"intervention":705,"totalTrials":93,"cells":875},{"EARLY_PHASE1":876,"PHASE1":878,"PHASE2":880,"PHASE3":886,"PHASE4":888,"NA":890},{"trials":877,"activeCount":97},[],{"trials":879,"activeCount":97},[],{"trials":881,"activeCount":93,"soonestReadout":691},[882],{"nctId":688,"briefTitle":689,"status":222,"phases":883,"primaryCompletion":691,"completion":691,"start":692,"enrollment":226,"conditions":884,"interventions":885},[86,87],[694],[679,696,697,698,699,700,701,702,703,704,705],{"trials":887,"activeCount":97},[],{"trials":889,"activeCount":97},[],{"trials":891,"activeCount":97},[],{"intervention":893,"totalTrials":93,"cells":894},"Zinc",{"EARLY_PHASE1":895,"PHASE1":897,"PHASE2":899,"PHASE3":911,"PHASE4":913,"NA":915},{"trials":896,"activeCount":97},[],{"trials":898,"activeCount":97},[],{"trials":900,"activeCount":93,"soonestReadout":905},[901],{"nctId":902,"briefTitle":903,"status":222,"phases":904,"primaryCompletion":905,"completion":905,"start":906,"enrollment":374,"conditions":907,"interventions":909},"NCT06567717","Zinc and Nicotinamide Riboside for Idiopathic Pulmonary Fibrosis",[87],"2027-01","2025-11-03",[908],"Idiopathic Pulmonary Fibrosis",[893,910],"Nicotinamide riboside",{"trials":912,"activeCount":97},[],{"trials":914,"activeCount":97},[],{"trials":916,"activeCount":97},[],{"intervention":910,"totalTrials":93,"cells":918},{"EARLY_PHASE1":919,"PHASE1":921,"PHASE2":923,"PHASE3":929,"PHASE4":931,"NA":933},{"trials":920,"activeCount":97},[],{"trials":922,"activeCount":97},[],{"trials":924,"activeCount":93,"soonestReadout":905},[925],{"nctId":902,"briefTitle":903,"status":222,"phases":926,"primaryCompletion":905,"completion":905,"start":906,"enrollment":374,"conditions":927,"interventions":928},[87],[908],[893,910],{"trials":930,"activeCount":97},[],{"trials":932,"activeCount":97},[],{"trials":934,"activeCount":97},[],{"intervention":936,"totalTrials":93,"cells":937},"Vytorin",{"EARLY_PHASE1":938,"PHASE1":940,"PHASE2":942,"PHASE3":955,"PHASE4":957,"NA":959},{"trials":939,"activeCount":97},[],{"trials":941,"activeCount":97},[],{"trials":943,"activeCount":93,"soonestReadout":948},[944],{"nctId":945,"briefTitle":946,"status":222,"phases":947,"primaryCompletion":948,"completion":949,"start":950,"enrollment":951,"conditions":952,"interventions":953},"NCT06437574","Intensive Cholesterol-Lowering and CD8+ T Cells in Prostate Cancer",[87],"2028-02-29","2028-05-31","2024-07-16",140,[26],[936,954],"Ezetimibe",{"trials":956,"activeCount":97},[],{"trials":958,"activeCount":97},[],{"trials":960,"activeCount":97},[],{"intervention":954,"totalTrials":93,"cells":962},{"EARLY_PHASE1":963,"PHASE1":965,"PHASE2":967,"PHASE3":973,"PHASE4":975,"NA":977},{"trials":964,"activeCount":97},[],{"trials":966,"activeCount":97},[],{"trials":968,"activeCount":93,"soonestReadout":948},[969],{"nctId":945,"briefTitle":946,"status":222,"phases":970,"primaryCompletion":948,"completion":949,"start":950,"enrollment":951,"conditions":971,"interventions":972},[87],[26],[936,954],{"trials":974,"activeCount":97},[],{"trials":976,"activeCount":97},[],{"trials":978,"activeCount":97},[],{"intervention":50,"totalTrials":93,"cells":980},{"EARLY_PHASE1":981,"PHASE1":983,"PHASE2":985,"PHASE3":992,"PHASE4":994,"NA":996},{"trials":982,"activeCount":97},[],{"trials":984,"activeCount":97},[],{"trials":986,"activeCount":93,"soonestReadout":49},[987],{"nctId":47,"briefTitle":48,"status":159,"phases":988,"primaryCompletion":49,"completion":49,"start":989,"enrollment":226,"conditions":990,"interventions":991},[87],"2022-09-23",[601,599,644],[50],{"trials":993,"activeCount":97},[],{"trials":995,"activeCount":97},[],{"trials":997,"activeCount":97},[],{"intervention":999,"totalTrials":93,"cells":1000},"Fluticasone Propionate 93 MCG\u002F1 ACTUATION Nasal Spray",{"EARLY_PHASE1":1001,"PHASE1":1003,"PHASE2":1005,"PHASE3":1018,"PHASE4":1020,"NA":1022},{"trials":1002,"activeCount":97},[],{"trials":1004,"activeCount":97},[],{"trials":1006,"activeCount":93,"soonestReadout":1011},[1007],{"nctId":1008,"briefTitle":1009,"status":222,"phases":1010,"primaryCompletion":1011,"completion":1012,"start":1013,"enrollment":1014,"conditions":1015,"interventions":1017},"NCT05275686","Effect of Novel Exhalational Delivery System With Fluticasone (EDS-FLU) on Eustachian Tube Dysfunction (ETD)",[87],"2027-06-30","2027-12-31","2022-04-20",80,[1016],"Eustachian Tube Dysfunction",[999],{"trials":1019,"activeCount":97},[],{"trials":1021,"activeCount":97},[],{"trials":1023,"activeCount":97},[],{"intervention":1025,"totalTrials":93,"cells":1026},"Low BPV Regimen",{"EARLY_PHASE1":1027,"PHASE1":1029,"PHASE2":1041,"PHASE3":1043,"PHASE4":1045,"NA":1047},{"trials":1028,"activeCount":97},[],{"trials":1030,"activeCount":93,"soonestReadout":1035},[1031],{"nctId":1032,"briefTitle":1033,"status":107,"phases":1034,"primaryCompletion":1035,"completion":1036,"start":1037,"enrollment":22,"conditions":1038,"interventions":1040},"NCT06012487","Correlates and Control of Blood Pressure Variability",[86],"2026-12-01","2026-12-31","2026-05-01",[1039],"Blood Pressure Variability",[1025],{"trials":1042,"activeCount":97},[],{"trials":1044,"activeCount":97},[],{"trials":1046,"activeCount":97},[],{"trials":1048,"activeCount":97},[],{"intervention":74,"totalTrials":93,"cells":1050},{"EARLY_PHASE1":1051,"PHASE1":1053,"PHASE2":1062,"PHASE3":1064,"PHASE4":1066,"NA":1068},{"trials":1052,"activeCount":97},[],{"trials":1054,"activeCount":93,"soonestReadout":73},[1055],{"nctId":71,"briefTitle":72,"status":159,"phases":1056,"primaryCompletion":73,"completion":73,"start":1057,"enrollment":1058,"conditions":1059,"interventions":1061},[86],"2021-07-22",16,[1060],"Retinitis Pigmentosa",[74],{"trials":1063,"activeCount":97},[],{"trials":1065,"activeCount":97},[],{"trials":1067,"activeCount":97},[],{"trials":1069,"activeCount":97},[],{"intervention":1071,"totalTrials":93,"cells":1072},"CNS10-NPC-GDNF",{"EARLY_PHASE1":1073,"PHASE1":1075,"PHASE2":1086,"PHASE3":1088,"PHASE4":1090,"NA":1092},{"trials":1074,"activeCount":97},[],{"trials":1076,"activeCount":93,"soonestReadout":1081},[1077],{"nctId":1078,"briefTitle":1079,"status":159,"phases":1080,"primaryCompletion":1081,"completion":1081,"start":1082,"enrollment":1058,"conditions":1083,"interventions":1085},"NCT05306457","CNS10-NPC-GDNF Delivered to the Motor Cortex for ALS",[86],"2026-10","2022-05-08",[1084],"Amyotrophic Lateral Sclerosis",[1071],{"trials":1087,"activeCount":97},[],{"trials":1089,"activeCount":97},[],{"trials":1091,"activeCount":97},[],{"trials":1093,"activeCount":97},[],{"intervention":69,"totalTrials":93,"cells":1095},{"EARLY_PHASE1":1096,"PHASE1":1098,"PHASE2":1107,"PHASE3":1109,"PHASE4":1111,"NA":1113},{"trials":1097,"activeCount":97},[],{"trials":1099,"activeCount":93,"soonestReadout":64},[1100],{"nctId":67,"briefTitle":68,"status":159,"phases":1101,"primaryCompletion":64,"completion":1102,"start":1103,"enrollment":1104,"conditions":1105,"interventions":1106},[86],"2027-04-30","2023-02-15",24,[908],[69],{"trials":1108,"activeCount":97},[],{"trials":1110,"activeCount":97},[],{"trials":1112,"activeCount":97},[],{"trials":1114,"activeCount":97},[],{"intervention":83,"totalTrials":237,"cells":1116},{"EARLY_PHASE1":1117,"PHASE1":1136,"PHASE2":1138,"PHASE3":1140,"PHASE4":1142,"NA":1155},{"trials":1118,"activeCount":93,"soonestReadout":82},[1119,1127],{"nctId":80,"briefTitle":81,"status":222,"phases":1120,"primaryCompletion":82,"completion":1121,"start":1122,"enrollment":268,"conditions":1123,"interventions":1126},[85],"2026-12","2022-10-20",[1124,1125],"Anxiety","Pancreatic Cancer",[83,83],{"nctId":1128,"briefTitle":1129,"status":387,"phases":1130,"primaryCompletion":1131,"completion":1131,"start":1132,"enrollment":97,"conditions":1133,"interventions":1135},"NCT02442739","Ketamine for Preventing Depression in Patients Undergoing Treatment for Pancreatic or Head and Neck Cancers",[85],"2017-11-03","2016-08-15",[1134,1125,21],"Head and Neck Cancer",[83],{"trials":1137,"activeCount":97},[],{"trials":1139,"activeCount":97},[],{"trials":1141,"activeCount":97},[],{"trials":1143,"activeCount":97},[1144],{"nctId":1145,"briefTitle":1146,"status":407,"phases":1147,"primaryCompletion":1148,"completion":1148,"start":1149,"enrollment":16,"conditions":1150,"interventions":1152},"NCT02252432","The Effects of Ketamine and Methadone on Postoperative Pain for Laminectomy",[89],"2023-01","2013-02",[1151],"Laminectomy",[83,1153,1154],"Methadone","Ketamine + methadone",{"trials":1156,"activeCount":97},[],{"intervention":60,"totalTrials":332,"cells":1158},{"EARLY_PHASE1":1159,"PHASE1":1167,"PHASE2":1169,"PHASE3":1183,"PHASE4":1185,"NA":1187},{"trials":1160,"activeCount":93,"soonestReadout":59},[1161],{"nctId":57,"briefTitle":58,"status":222,"phases":1162,"primaryCompletion":59,"completion":1121,"start":1163,"enrollment":1104,"conditions":1164,"interventions":1166},[85],"2023-06-01",[1165],"Chronic Pancreatitis",[60],{"trials":1168,"activeCount":97},[],{"trials":1170,"activeCount":97},[1171],{"nctId":1172,"briefTitle":1173,"status":1174,"phases":1175,"primaryCompletion":1176,"completion":1176,"start":1177,"conditions":1178,"interventions":1181},"NCT00064376","Paricalcitol in Treating Patients With Myelodysplastic Syndrome","COMPLETED",[87],"2005-11","2003-05",[1179,1180],"Leukemia","Myelodysplastic Syndromes",[1182],"paricalcitol",{"trials":1184,"activeCount":97},[],{"trials":1186,"activeCount":97},[],{"trials":1188,"activeCount":97},[],{"intervention":1190,"totalTrials":93,"cells":1191},"Simvastatin",{"EARLY_PHASE1":1192,"PHASE1":1204,"PHASE2":1206,"PHASE3":1208,"PHASE4":1210,"NA":1212},{"trials":1193,"activeCount":93,"soonestReadout":1121},[1194],{"nctId":1195,"briefTitle":1196,"status":222,"phases":1197,"primaryCompletion":1121,"completion":1198,"start":1199,"enrollment":1200,"conditions":1201,"interventions":1203},"NCT05771675","Simvastatin Treatment to Improve Patient-reported Outcomes in Patients With Chronic Pancreatitis",[85],"2027-06","2024-10-24",90,[1202,1165],"Recurrent Acute Pancreatitis",[1190],{"trials":1205,"activeCount":97},[],{"trials":1207,"activeCount":97},[],{"trials":1209,"activeCount":97},[],{"trials":1211,"activeCount":97},[],{"trials":1213,"activeCount":97},[],{"intervention":1215,"totalTrials":93,"cells":1216},"local anaesthetic",{"EARLY_PHASE1":1217,"PHASE1":1228,"PHASE2":1230,"PHASE3":1232,"PHASE4":1234,"NA":1236},{"trials":1218,"activeCount":93,"soonestReadout":1223},[1219],{"nctId":1220,"briefTitle":1221,"status":159,"phases":1222,"primaryCompletion":1223,"completion":1223,"start":1224,"enrollment":429,"conditions":1225,"interventions":1227},"NCT05747469","Use of Allograft Adipose Matrix for Small Joint Arthritis of the Hand",[85],"2027-01-01","2023-08-28",[1226],"Osteoarthritis Hand",[1215],{"trials":1229,"activeCount":97},[],{"trials":1231,"activeCount":97},[],{"trials":1233,"activeCount":97},[],{"trials":1235,"activeCount":97},[],{"trials":1237,"activeCount":97},[],{"intervention":45,"totalTrials":332,"cells":1239},{"EARLY_PHASE1":1240,"PHASE1":1242,"PHASE2":1244,"PHASE3":1246,"PHASE4":1248,"NA":1250},{"trials":1241,"activeCount":97},[],{"trials":1243,"activeCount":97},[],{"trials":1245,"activeCount":97},[],{"trials":1247,"activeCount":97},[],{"trials":1249,"activeCount":97},[],{"trials":1251,"activeCount":93,"soonestReadout":44},[1252,1262],{"nctId":1253,"briefTitle":1254,"status":264,"phases":1255,"primaryCompletion":1256,"completion":1256,"start":1257,"enrollment":302,"conditions":1258,"interventions":1260},"NCT03064295","Whole-Heart Myocardial Blood Flow Quantification Using MRI",[],"2025-01-01","2018-03-01",[18,1259],"Coronary Microvascular Disease",[45,1261],"Pharmacologic Stress Agent",{"nctId":42,"briefTitle":43,"status":222,"phases":1263,"primaryCompletion":44,"completion":1036,"start":1264,"enrollment":1265,"conditions":1266,"interventions":1268},[90],"2018-07-30",150,[1267],"Coronary Atherosclerosis",[45,1269],"Beta blocker",{"intervention":1271,"totalTrials":93,"cells":1272},"Warfarin",{"EARLY_PHASE1":1273,"PHASE1":1275,"PHASE2":1277,"PHASE3":1279,"PHASE4":1281,"NA":1283},{"trials":1274,"activeCount":97},[],{"trials":1276,"activeCount":97},[],{"trials":1278,"activeCount":97},[],{"trials":1280,"activeCount":97},[],{"trials":1282,"activeCount":97},[],{"trials":1284,"activeCount":93,"soonestReadout":1121},[1285],{"nctId":1286,"briefTitle":1287,"status":222,"phases":1288,"primaryCompletion":1121,"completion":426,"start":1289,"enrollment":1290,"conditions":1291,"interventions":1293},"NCT02318342","Assessment of TRanscathetEr and Surgical Aortic BiOprosthetic Valve Thrombosis and Its TrEatment With Anticoagulation",[90],"2014-12",3000,[1292],"Prosthetic Valve Thrombosis",[1271],{"intervention":283,"totalTrials":93,"cells":1295},{"EARLY_PHASE1":1296,"PHASE1":1298,"PHASE2":1300,"PHASE3":1302,"PHASE4":1304,"NA":1306},{"trials":1297,"activeCount":97},[],{"trials":1299,"activeCount":97},[],{"trials":1301,"activeCount":97},[],{"trials":1303,"activeCount":97},[],{"trials":1305,"activeCount":97},[],{"trials":1307,"activeCount":93,"soonestReadout":277},[1308],{"nctId":274,"briefTitle":275,"status":222,"phases":1309,"primaryCompletion":277,"completion":277,"start":278,"enrollment":279,"conditions":1310,"interventions":1311},[90],[281],[236,283],{"intervention":1269,"totalTrials":93,"cells":1313},{"EARLY_PHASE1":1314,"PHASE1":1316,"PHASE2":1318,"PHASE3":1320,"PHASE4":1322,"NA":1324},{"trials":1315,"activeCount":97},[],{"trials":1317,"activeCount":97},[],{"trials":1319,"activeCount":97},[],{"trials":1321,"activeCount":97},[],{"trials":1323,"activeCount":97},[],{"trials":1325,"activeCount":93,"soonestReadout":44},[1326],{"nctId":42,"briefTitle":43,"status":222,"phases":1327,"primaryCompletion":44,"completion":1036,"start":1264,"enrollment":1265,"conditions":1328,"interventions":1329},[90],[1267],[45,1269],{"intervention":1331,"totalTrials":1332,"cells":1333},"Saline",4,{"EARLY_PHASE1":1334,"PHASE1":1336,"PHASE2":1338,"PHASE3":1340,"PHASE4":1342,"NA":1384},{"trials":1335,"activeCount":97},[],{"trials":1337,"activeCount":97},[],{"trials":1339,"activeCount":97},[],{"trials":1341,"activeCount":97},[],{"trials":1343,"activeCount":97},[1344,1354,1363,1374],{"nctId":1345,"briefTitle":1346,"status":407,"phases":1347,"primaryCompletion":1348,"completion":1348,"start":1349,"enrollment":1350,"conditions":1351,"interventions":1352},"NCT01179113","Esmolol Infusion During Laminectomy: Effect on Quality of Recovery",[89],"2015-05","2011-06",33,[1151],[1353,1331],"Esmolol",{"nctId":1355,"briefTitle":1356,"status":1174,"phases":1357,"primaryCompletion":1149,"completion":1149,"start":1349,"enrollment":111,"conditions":1358,"interventions":1361},"NCT01368809","Effect of Fentanyl on Coughing and Recovery After Anesthesia With an LMA Laryngeal Mask Airway)for Airway Management",[89],[1359,1360],"Ambulatory Surgery","Coughing",[1331,1362],"Fentanyl",{"nctId":1364,"briefTitle":1365,"status":1174,"phases":1366,"primaryCompletion":1367,"completion":1367,"start":389,"enrollment":1368,"conditions":1369,"interventions":1371},"NCT01976845","Efficacy of Propofol or Midazolam Compare to Placebo for Preoperative Medication",[89],"2015-07",139,[1370],"Elective Orthopedic Surgery",[1372,1373,1331],"Midazolam","Propofol",{"nctId":1375,"briefTitle":1376,"status":1174,"phases":1377,"primaryCompletion":1378,"completion":1378,"start":1379,"enrollment":374,"conditions":1380,"interventions":1382},"NCT01975285","Efficacy of Popliteal Nerve Blocks With and Without Dexamethasone on the Duration of Analgesia for Foot & Ankle Surgery",[89],"2014-06","2013-08",[1381],"Foot and Ankle Procedures",[1383,1331],"Dexamethasone",{"trials":1385,"activeCount":97},[],{"intervention":1353,"totalTrials":237,"cells":1387},{"EARLY_PHASE1":1388,"PHASE1":1390,"PHASE2":1392,"PHASE3":1394,"PHASE4":1396,"NA":1427},{"trials":1389,"activeCount":97},[],{"trials":1391,"activeCount":97},[],{"trials":1393,"activeCount":97},[],{"trials":1395,"activeCount":97},[],{"trials":1397,"activeCount":97},[1398,1402,1416],{"nctId":1345,"briefTitle":1346,"status":407,"phases":1399,"primaryCompletion":1348,"completion":1348,"start":1349,"enrollment":1350,"conditions":1400,"interventions":1401},[89],[1151],[1353,1331],{"nctId":1403,"briefTitle":1404,"status":407,"phases":1405,"primaryCompletion":1406,"completion":1406,"start":1407,"enrollment":1408,"conditions":1409,"interventions":1413},"NCT01114997","Effect of Lidocaine and Esmolol to Improve the Quality of Recovery",[89],"2015-06","2010-04",32,[33,1410,1411,1412],"Constipation","Nausea","Vomiting",[1414,1353,1415],"Lidocaine","Lidocaine + Esmolol",{"nctId":1417,"briefTitle":1418,"status":1174,"phases":1419,"primaryCompletion":1420,"completion":1421,"start":1422,"enrollment":1423,"conditions":1424,"interventions":1425},"NCT01114971","Labetalol and Esmolol: Vital Signs and Post Operative Pain Management",[89],"2014-07-30","2018-07-31","2009-09-03",75,[281],[1362,1426,1353],"Labetalol",{"trials":1428,"activeCount":97},[],{"intervention":1430,"totalTrials":237,"cells":1431},"Tadalafil",{"EARLY_PHASE1":1432,"PHASE1":1445,"PHASE2":1461,"PHASE3":1463,"PHASE4":1465,"NA":1477},{"trials":1433,"activeCount":97},[1434],{"nctId":1435,"briefTitle":1436,"status":1174,"phases":1437,"primaryCompletion":1438,"completion":1438,"start":1439,"enrollment":1440,"conditions":1441,"interventions":1443},"NCT01359670","Tadalafil and Sildenafil for Duchenne Muscular Dystrophy",[85],"2013-05","2011-05",30,[1442],"Duchenne Muscular Dystrophy",[1430,1444],"Sildenafil",{"trials":1446,"activeCount":97},[1447],{"nctId":1448,"briefTitle":1449,"status":407,"phases":1450,"primaryCompletion":1451,"completion":1452,"start":1453,"enrollment":374,"conditions":1454,"interventions":1457},"NCT03166787","Hookah Smoking, Carbon Monoxide, and Coronary Endothelial Function",[86],"2020-04-15","2020-10-15","2017-08-15",[1455,1456],"Smoking","Endothelial Dysfunction",[1458,1459,1460],"Carbon Monoxide inhalation","vitamin C","tadalafil",{"trials":1462,"activeCount":97},[],{"trials":1464,"activeCount":97},[],{"trials":1466,"activeCount":97},[1467],{"nctId":1468,"briefTitle":1469,"status":1174,"phases":1470,"primaryCompletion":1471,"completion":1471,"start":1472,"enrollment":1473,"conditions":1474,"interventions":1476},"NCT01070511","Tadalafil in Becker Muscular Dystrophy",[89],"2012-12","2010-01",48,[1475],"Becker Muscular Dystrophy",[1430],{"trials":1478,"activeCount":97},[],{"intervention":1480,"totalTrials":332,"cells":1481},"Liraglutide",{"EARLY_PHASE1":1482,"PHASE1":1484,"PHASE2":1486,"PHASE3":1498,"PHASE4":1500,"NA":1512},{"trials":1483,"activeCount":97},[],{"trials":1485,"activeCount":97},[],{"trials":1487,"activeCount":97},[1488],{"nctId":1489,"briefTitle":1490,"status":1174,"phases":1491,"primaryCompletion":1492,"completion":1492,"start":1493,"enrollment":1494,"conditions":1495,"interventions":1497},"NCT02953665","Safety and Efficacy of Liraglutide in Parkinson's Disease",[87],"2022-08-03","2017-04-03",63,[1496],"Parkinson Disease",[1480],{"trials":1499,"activeCount":97},[],{"trials":1501,"activeCount":97},[1502],{"nctId":1503,"briefTitle":1504,"status":387,"phases":1505,"primaryCompletion":1506,"completion":1507,"start":1508,"enrollment":97,"conditions":1509,"interventions":1511},"NCT02198209","Liraglutide Actions on the Liver: Effects on Glucose Phosphorylation",[89],"2020-07","2020-12","2019-12",[1510],"Type 2 Diabetes",[1480],{"trials":1513,"activeCount":97},[],{"intervention":1362,"totalTrials":332,"cells":1515},{"EARLY_PHASE1":1516,"PHASE1":1518,"PHASE2":1520,"PHASE3":1522,"PHASE4":1524,"NA":1534},{"trials":1517,"activeCount":97},[],{"trials":1519,"activeCount":97},[],{"trials":1521,"activeCount":97},[],{"trials":1523,"activeCount":97},[],{"trials":1525,"activeCount":97},[1526,1530],{"nctId":1355,"briefTitle":1356,"status":1174,"phases":1527,"primaryCompletion":1149,"completion":1149,"start":1349,"enrollment":111,"conditions":1528,"interventions":1529},[89],[1359,1360],[1331,1362],{"nctId":1417,"briefTitle":1418,"status":1174,"phases":1531,"primaryCompletion":1420,"completion":1421,"start":1422,"enrollment":1423,"conditions":1532,"interventions":1533},[89],[281],[1362,1426,1353],{"trials":1535,"activeCount":97},[],{"intervention":1537,"totalTrials":332,"cells":1538},"Niaspan",{"EARLY_PHASE1":1539,"PHASE1":1541,"PHASE2":1543,"PHASE3":1545,"PHASE4":1547,"NA":1566},{"trials":1540,"activeCount":97},[],{"trials":1542,"activeCount":97},[],{"trials":1544,"activeCount":97},[],{"trials":1546,"activeCount":97},[],{"trials":1548,"activeCount":97},[1549,1557],{"nctId":1550,"briefTitle":1551,"status":1174,"phases":1552,"primaryCompletion":1176,"completion":1176,"start":1553,"enrollment":1554,"conditions":1555,"interventions":1556},"NCT00590629","Benefit of Elevation of HDL-C on Cardiovascular Outcomes in Women",[89],"2002-06",43,[18],[1537],{"nctId":1558,"briefTitle":1559,"status":1174,"phases":1560,"primaryCompletion":1561,"completion":1561,"start":1562,"enrollment":1554,"conditions":1563,"interventions":1565},"NCT01921010","Benefit of Elevation of HDL-C in Women",[89],"2005-06","2003-06",[1564],"Cardiovascular Outcomes",[1537],{"trials":1567,"activeCount":97},[],{"intervention":1414,"totalTrials":332,"cells":1569},{"EARLY_PHASE1":1570,"PHASE1":1572,"PHASE2":1574,"PHASE3":1576,"PHASE4":1578,"NA":1594},{"trials":1571,"activeCount":97},[],{"trials":1573,"activeCount":97},[],{"trials":1575,"activeCount":97},[],{"trials":1577,"activeCount":97},[],{"trials":1579,"activeCount":97},[1580,1590],{"nctId":1581,"briefTitle":1582,"status":387,"phases":1583,"primaryCompletion":1584,"completion":1584,"start":1349,"enrollment":97,"conditions":1585,"interventions":1589},"NCT01179100","How Lidocaine Affects Outcomes In Orthopedic Surgery Patients",[89],"2015-10",[1586,1587,1588],"General Anesthesia","Surgeries Requiring A Minimum One Day Hospitalization","Elderly",[1414],{"nctId":1403,"briefTitle":1404,"status":407,"phases":1591,"primaryCompletion":1406,"completion":1406,"start":1407,"enrollment":1408,"conditions":1592,"interventions":1593},[89],[33,1410,1411,1412],[1414,1353,1415],{"trials":1595,"activeCount":97},[],{"intervention":1597,"totalTrials":332,"cells":1598},"Allopurinol",{"EARLY_PHASE1":1599,"PHASE1":1601,"PHASE2":1603,"PHASE3":1605,"PHASE4":1607,"NA":1629},{"trials":1600,"activeCount":97},[],{"trials":1602,"activeCount":97},[],{"trials":1604,"activeCount":97},[],{"trials":1606,"activeCount":97},[],{"trials":1608,"activeCount":97},[1609,1620],{"nctId":1610,"briefTitle":1611,"status":1174,"phases":1612,"primaryCompletion":1613,"completion":1613,"start":1614,"enrollment":136,"conditions":1615,"interventions":1619},"NCT00643123","Allopurinol Add-on Treatment for Refractory Mania",[89],"2010-06","2007-09",[1616,1617,1618],"Bipolar Disorder","Mixed Mania","Treatment-Resistant Mania",[1597],{"nctId":1621,"briefTitle":1622,"status":407,"phases":1623,"primaryCompletion":1624,"completion":1624,"start":1625,"enrollment":226,"conditions":1626,"interventions":1628},"NCT00732251","Allopurinol Maintenance Study for Bipolar Disorder",[89],"2012-01","2008-08",[1616,1627,1617],"Mania",[1597],{"trials":1630,"activeCount":97},[],{"intervention":1632,"totalTrials":93,"cells":1633},"Octreotide LAR 30 MG",{"EARLY_PHASE1":1634,"PHASE1":1636,"PHASE2":1638,"PHASE3":1640,"PHASE4":1642,"NA":1652},{"trials":1635,"activeCount":97},[],{"trials":1637,"activeCount":97},[],{"trials":1639,"activeCount":97},[],{"trials":1641,"activeCount":97},[],{"trials":1643,"activeCount":97},[1644],{"nctId":1645,"briefTitle":1646,"status":1174,"phases":1647,"primaryCompletion":1648,"completion":1648,"start":1649,"enrollment":226,"conditions":1650,"interventions":1651},"NCT00552071","Ultrasound Guided Octreotide LAR Injection in Acromegaly",[89],"2014-03","2007-07",[30],[1632],{"trials":1653,"activeCount":97},[],{"intervention":1655,"totalTrials":93,"cells":1656},"Ergocalciferol",{"EARLY_PHASE1":1657,"PHASE1":1659,"PHASE2":1661,"PHASE3":1663,"PHASE4":1665,"NA":1677},{"trials":1658,"activeCount":97},[],{"trials":1660,"activeCount":97},[],{"trials":1662,"activeCount":97},[],{"trials":1664,"activeCount":97},[],{"trials":1666,"activeCount":97},[1667],{"nctId":1668,"briefTitle":1669,"status":1174,"phases":1670,"primaryCompletion":1671,"completion":1671,"start":1672,"enrollment":1673,"conditions":1674,"interventions":1676},"NCT01568255","Is Treatment of Vitamin D Deficiency Associated With Resolution of Statin-Induced Muscular Symptoms",[89],"2019-06","2012-03",11,[1675],"Myopathic Symptoms",[1655],{"trials":1678,"activeCount":97},[],{"intervention":1680,"totalTrials":93,"cells":1681},"Mycophenolate Sodium",{"EARLY_PHASE1":1682,"PHASE1":1684,"PHASE2":1686,"PHASE3":1688,"PHASE4":1690,"NA":1701},{"trials":1683,"activeCount":97},[],{"trials":1685,"activeCount":97},[],{"trials":1687,"activeCount":97},[],{"trials":1689,"activeCount":97},[],{"trials":1691,"activeCount":97},[1692],{"nctId":1693,"briefTitle":1694,"status":1174,"phases":1695,"primaryCompletion":1696,"completion":1696,"start":1697,"enrollment":1673,"conditions":1698,"interventions":1700},"NCT00574197","Enteric-coated Mycophenolate Sodium (Myfortic®) in Heart Transplant Recipients",[89],"2009-12","2006-06",[1699,376],"Gastrointestinal Symptoms",[1680],{"trials":1702,"activeCount":97},[],{"intervention":1704,"totalTrials":93,"cells":1705},"Extended-release tacrolimus",{"EARLY_PHASE1":1706,"PHASE1":1708,"PHASE2":1710,"PHASE3":1712,"PHASE4":1714,"NA":1726},{"trials":1707,"activeCount":97},[],{"trials":1709,"activeCount":97},[],{"trials":1711,"activeCount":97},[],{"trials":1713,"activeCount":97},[],{"trials":1715,"activeCount":97},[1716],{"nctId":1717,"briefTitle":1718,"status":1174,"phases":1719,"primaryCompletion":1720,"completion":1720,"start":1721,"enrollment":268,"conditions":1722,"interventions":1724},"NCT04225988","Comparison of Tacrolimus Extended-Release (Envarsus XR) to Tacrolimus Immediate-Release in Human Leukocyte Antigen (HLA) Sensitized Kidney Transplant Recipients",[89],"2023-07-11","2020-01-09",[1723],"Kidney Transplant Rejection",[1704,1725],"Immediate-release tacrolimus",{"trials":1727,"activeCount":97},[],{"intervention":1725,"totalTrials":93,"cells":1729},{"EARLY_PHASE1":1730,"PHASE1":1732,"PHASE2":1734,"PHASE3":1736,"PHASE4":1738,"NA":1744},{"trials":1731,"activeCount":97},[],{"trials":1733,"activeCount":97},[],{"trials":1735,"activeCount":97},[],{"trials":1737,"activeCount":97},[],{"trials":1739,"activeCount":97},[1740],{"nctId":1717,"briefTitle":1718,"status":1174,"phases":1741,"primaryCompletion":1720,"completion":1720,"start":1721,"enrollment":268,"conditions":1742,"interventions":1743},[89],[1723],[1704,1725],{"trials":1745,"activeCount":97},[],{"intervention":1372,"totalTrials":93,"cells":1747},{"EARLY_PHASE1":1748,"PHASE1":1750,"PHASE2":1752,"PHASE3":1754,"PHASE4":1756,"NA":1762},{"trials":1749,"activeCount":97},[],{"trials":1751,"activeCount":97},[],{"trials":1753,"activeCount":97},[],{"trials":1755,"activeCount":97},[],{"trials":1757,"activeCount":97},[1758],{"nctId":1364,"briefTitle":1365,"status":1174,"phases":1759,"primaryCompletion":1367,"completion":1367,"start":389,"enrollment":1368,"conditions":1760,"interventions":1761},[89],[1370],[1372,1373,1331],{"trials":1763,"activeCount":97},[],{"intervention":1373,"totalTrials":93,"cells":1765},{"EARLY_PHASE1":1766,"PHASE1":1768,"PHASE2":1770,"PHASE3":1772,"PHASE4":1774,"NA":1780},{"trials":1767,"activeCount":97},[],{"trials":1769,"activeCount":97},[],{"trials":1771,"activeCount":97},[],{"trials":1773,"activeCount":97},[],{"trials":1775,"activeCount":97},[1776],{"nctId":1364,"briefTitle":1365,"status":1174,"phases":1777,"primaryCompletion":1367,"completion":1367,"start":389,"enrollment":1368,"conditions":1778,"interventions":1779},[89],[1370],[1372,1373,1331],{"trials":1781,"activeCount":97},[],{"intervention":1783,"totalTrials":93,"cells":1784},"Oral Contraceptive Pill, norethindrn a-e estradiol-iron",{"EARLY_PHASE1":1785,"PHASE1":1787,"PHASE2":1789,"PHASE3":1791,"PHASE4":1793,"NA":1806},{"trials":1786,"activeCount":97},[],{"trials":1788,"activeCount":97},[],{"trials":1790,"activeCount":97},[],{"trials":1792,"activeCount":97},[],{"trials":1794,"activeCount":97},[1795],{"nctId":1796,"briefTitle":1797,"status":1174,"phases":1798,"primaryCompletion":1799,"completion":1800,"start":1801,"enrollment":1802,"conditions":1803,"interventions":1805},"NCT04899778","Do Oral Contraceptives Protect Against ACL Injuries in Female Athletes",[89],"2023-11-20","2024-06-30","2021-09-29",73,[1804],"Ligament Injury",[1783],{"trials":1807,"activeCount":97},[],{"intervention":1809,"totalTrials":93,"cells":1810},"Ketamine high-dose",{"EARLY_PHASE1":1811,"PHASE1":1813,"PHASE2":1815,"PHASE3":1817,"PHASE4":1819,"NA":1830},{"trials":1812,"activeCount":97},[],{"trials":1814,"activeCount":97},[],{"trials":1816,"activeCount":97},[],{"trials":1818,"activeCount":97},[],{"trials":1820,"activeCount":97},[1821],{"nctId":1822,"briefTitle":1823,"status":407,"phases":1824,"primaryCompletion":1289,"completion":1289,"start":1439,"enrollment":1825,"conditions":1826,"interventions":1828},"NCT01365195","Effect of Ketamine on Postoperative Clinical Outcomes",[89],21,[1827],"Colorectal Surgery",[1809,1829],"Ketamine low-dose",{"trials":1831,"activeCount":97},[],{"intervention":1829,"totalTrials":93,"cells":1833},{"EARLY_PHASE1":1834,"PHASE1":1836,"PHASE2":1838,"PHASE3":1840,"PHASE4":1842,"NA":1848},{"trials":1835,"activeCount":97},[],{"trials":1837,"activeCount":97},[],{"trials":1839,"activeCount":97},[],{"trials":1841,"activeCount":97},[],{"trials":1843,"activeCount":97},[1844],{"nctId":1822,"briefTitle":1823,"status":407,"phases":1845,"primaryCompletion":1289,"completion":1289,"start":1439,"enrollment":1825,"conditions":1846,"interventions":1847},[89],[1827],[1809,1829],{"trials":1849,"activeCount":97},[],{"intervention":1851,"totalTrials":93,"cells":1852},"ERAS",{"EARLY_PHASE1":1853,"PHASE1":1855,"PHASE2":1857,"PHASE3":1859,"PHASE4":1861,"NA":1874},{"trials":1854,"activeCount":97},[],{"trials":1856,"activeCount":97},[],{"trials":1858,"activeCount":97},[],{"trials":1860,"activeCount":97},[],{"trials":1862,"activeCount":97},[1863],{"nctId":1864,"briefTitle":1865,"status":1174,"phases":1866,"primaryCompletion":1867,"completion":1867,"start":1868,"enrollment":1869,"conditions":1870,"interventions":1872},"NCT03738904","Prospective Randomized Controlled Trial of an Enhanced Recovery Protocol for Anorectal Surgery",[89],"2022-08-18","2018-10-26",111,[1871],"Anorectal Disorder",[1851,1873],"Standard of care",{"trials":1875,"activeCount":97},[],{"intervention":1873,"totalTrials":93,"cells":1877},{"EARLY_PHASE1":1878,"PHASE1":1880,"PHASE2":1882,"PHASE3":1884,"PHASE4":1886,"NA":1892},{"trials":1879,"activeCount":97},[],{"trials":1881,"activeCount":97},[],{"trials":1883,"activeCount":97},[],{"trials":1885,"activeCount":97},[],{"trials":1887,"activeCount":97},[1888],{"nctId":1864,"briefTitle":1865,"status":1174,"phases":1889,"primaryCompletion":1867,"completion":1867,"start":1868,"enrollment":1869,"conditions":1890,"interventions":1891},[89],[1871],[1851,1873],{"trials":1893,"activeCount":97},[],{"intervention":1895,"totalTrials":93,"cells":1896},"CeFAZolin 1000 MG",{"EARLY_PHASE1":1897,"PHASE1":1899,"PHASE2":1901,"PHASE3":1903,"PHASE4":1905,"NA":1919},{"trials":1898,"activeCount":97},[],{"trials":1900,"activeCount":97},[],{"trials":1902,"activeCount":97},[],{"trials":1904,"activeCount":97},[],{"trials":1906,"activeCount":97},[1907],{"nctId":1908,"briefTitle":1909,"status":407,"phases":1910,"primaryCompletion":1911,"completion":1911,"start":1912,"enrollment":1673,"conditions":1913,"interventions":1917},"NCT03478163","Antibiotics During Intrauterine Balloon Tamponade Placement",[89],"2021-05-03","2018-03-08",[1914,1915,1916],"Obstetric Complication","Postpartum Hemorrhage","Postpartum Endometritis",[1895,1918],"Clindamycin 900 MG in 6 ML",{"trials":1920,"activeCount":97},[],{"intervention":1918,"totalTrials":93,"cells":1922},{"EARLY_PHASE1":1923,"PHASE1":1925,"PHASE2":1927,"PHASE3":1929,"PHASE4":1931,"NA":1937},{"trials":1924,"activeCount":97},[],{"trials":1926,"activeCount":97},[],{"trials":1928,"activeCount":97},[],{"trials":1930,"activeCount":97},[],{"trials":1932,"activeCount":97},[1933],{"nctId":1908,"briefTitle":1909,"status":407,"phases":1934,"primaryCompletion":1911,"completion":1911,"start":1912,"enrollment":1673,"conditions":1935,"interventions":1936},[89],[1914,1915,1916],[1895,1918],{"trials":1938,"activeCount":97},[],{"intervention":1940,"totalTrials":93,"cells":1941},"Thiazide Treatment Group",{"EARLY_PHASE1":1942,"PHASE1":1944,"PHASE2":1946,"PHASE3":1948,"PHASE4":1950,"NA":1964},{"trials":1943,"activeCount":97},[],{"trials":1945,"activeCount":97},[],{"trials":1947,"activeCount":97},[],{"trials":1949,"activeCount":97},[],{"trials":1951,"activeCount":97},[1952],{"nctId":1953,"briefTitle":1954,"status":387,"phases":1955,"primaryCompletion":1956,"completion":1957,"start":1958,"enrollment":97,"conditions":1959,"interventions":1961},"NCT03319823","Treating Nocturnal Hypertension and Nocturia in African American Men",[89],"2019-02-13","2021-02-01","2017-10-25",[1960],"High Blood Pressure",[1940,1962,1963],"Intensified Thiazide Treatment Group","Combination Medication Treatment Group",{"trials":1965,"activeCount":97},[],{"intervention":1962,"totalTrials":93,"cells":1967},{"EARLY_PHASE1":1968,"PHASE1":1970,"PHASE2":1972,"PHASE3":1974,"PHASE4":1976,"NA":1982},{"trials":1969,"activeCount":97},[],{"trials":1971,"activeCount":97},[],{"trials":1973,"activeCount":97},[],{"trials":1975,"activeCount":97},[],{"trials":1977,"activeCount":97},[1978],{"nctId":1953,"briefTitle":1954,"status":387,"phases":1979,"primaryCompletion":1956,"completion":1957,"start":1958,"enrollment":97,"conditions":1980,"interventions":1981},[89],[1960],[1940,1962,1963],{"trials":1983,"activeCount":97},[],{"intervention":1963,"totalTrials":93,"cells":1985},{"EARLY_PHASE1":1986,"PHASE1":1988,"PHASE2":1990,"PHASE3":1992,"PHASE4":1994,"NA":2000},{"trials":1987,"activeCount":97},[],{"trials":1989,"activeCount":97},[],{"trials":1991,"activeCount":97},[],{"trials":1993,"activeCount":97},[],{"trials":1995,"activeCount":97},[1996],{"nctId":1953,"briefTitle":1954,"status":387,"phases":1997,"primaryCompletion":1956,"completion":1957,"start":1958,"enrollment":97,"conditions":1998,"interventions":1999},[89],[1960],[1940,1962,1963],{"trials":2001,"activeCount":97},[],{"intervention":1383,"totalTrials":93,"cells":2003},{"EARLY_PHASE1":2004,"PHASE1":2006,"PHASE2":2008,"PHASE3":2010,"PHASE4":2012,"NA":2018},{"trials":2005,"activeCount":97},[],{"trials":2007,"activeCount":97},[],{"trials":2009,"activeCount":97},[],{"trials":2011,"activeCount":97},[],{"trials":2013,"activeCount":97},[2014],{"nctId":1375,"briefTitle":1376,"status":1174,"phases":2015,"primaryCompletion":1378,"completion":1378,"start":1379,"enrollment":374,"conditions":2016,"interventions":2017},[89],[1381],[1383,1331],{"trials":2019,"activeCount":97},[],{"intervention":2021,"totalTrials":93,"cells":2022},"Pentoxifylline Oral Product",{"EARLY_PHASE1":2023,"PHASE1":2025,"PHASE2":2027,"PHASE3":2029,"PHASE4":2031,"NA":2043},{"trials":2024,"activeCount":97},[],{"trials":2026,"activeCount":97},[],{"trials":2028,"activeCount":97},[],{"trials":2030,"activeCount":97},[],{"trials":2032,"activeCount":97},[2033],{"nctId":2034,"briefTitle":2035,"status":387,"phases":2036,"primaryCompletion":2037,"completion":2037,"start":2038,"enrollment":97,"conditions":2039,"interventions":2042},"NCT04391231","HEMolysis in a Percutaneous Axial Flow LVAD, Effects of Pentoxifylline in a Randomized Controlled Trial",[89],"2022-06-01","2020-06-01",[2040,2041],"Hemolysis Intravascular","Acute Decompensated Heart Failure",[2021],{"trials":2044,"activeCount":97},[],{"intervention":2046,"totalTrials":93,"cells":2047},"Liposomal bupivacaine",{"EARLY_PHASE1":2048,"PHASE1":2050,"PHASE2":2052,"PHASE3":2054,"PHASE4":2056,"NA":2075},{"trials":2049,"activeCount":97},[],{"trials":2051,"activeCount":97},[],{"trials":2053,"activeCount":97},[],{"trials":2055,"activeCount":97},[],{"trials":2057,"activeCount":97},[2058],{"nctId":2059,"briefTitle":2060,"status":1174,"phases":2061,"primaryCompletion":2062,"completion":2062,"start":2063,"enrollment":2064,"conditions":2065,"interventions":2073},"NCT03723447","Intraoperative TAP Block With Bupivacaine\u002FDexamethasone Against Liposomal Bupivacaine (Exparel®)",[89],"2019-10-29","2018-10-23",102,[2066,694,2067,2068,228,2069,2070,33,2071,2072],"Pain, Postoperative","Inflammatory Bowel Diseases","Colorectal Cancer","Gastrointestinal Disease","Digestive System Disease","Pain, Neuropathic","Intestinal Disease",[2046,2074],"Bupivacaine\u002Fepinephrine\u002Fdexamethasone",{"trials":2076,"activeCount":97},[],{"intervention":2074,"totalTrials":93,"cells":2078},{"EARLY_PHASE1":2079,"PHASE1":2081,"PHASE2":2083,"PHASE3":2085,"PHASE4":2087,"NA":2093},{"trials":2080,"activeCount":97},[],{"trials":2082,"activeCount":97},[],{"trials":2084,"activeCount":97},[],{"trials":2086,"activeCount":97},[],{"trials":2088,"activeCount":97},[2089],{"nctId":2059,"briefTitle":2060,"status":1174,"phases":2090,"primaryCompletion":2062,"completion":2062,"start":2063,"enrollment":2064,"conditions":2091,"interventions":2092},[89],[2066,694,2067,2068,228,2069,2070,33,2071,2072],[2046,2074],{"trials":2094,"activeCount":97},[],{"intervention":2096,"totalTrials":93,"cells":2097},"Tacrolimus Extended-Release Oral",{"EARLY_PHASE1":2098,"PHASE1":2100,"PHASE2":2102,"PHASE3":2104,"PHASE4":2106,"NA":2117},{"trials":2099,"activeCount":97},[],{"trials":2101,"activeCount":97},[],{"trials":2103,"activeCount":97},[],{"trials":2105,"activeCount":97},[],{"trials":2107,"activeCount":97},[2108],{"nctId":2109,"briefTitle":2110,"status":1174,"phases":2111,"primaryCompletion":2112,"completion":2112,"start":2113,"enrollment":268,"conditions":2114,"interventions":2116},"NCT03194321","Trial to Evaluate Safety and Tolerability of Tacrolimus Extended-Release (Astagraf XL) in Human Leukocyte Antigen (HLA) Sensitized Kidney Transplant Recipients",[89],"2020-10-27","2017-09-11",[2115],"End Stage Renal Disease",[2096],{"trials":2118,"activeCount":97},[],{"intervention":2120,"totalTrials":93,"cells":2121},"Ertugliflozin",{"EARLY_PHASE1":2122,"PHASE1":2124,"PHASE2":2126,"PHASE3":2128,"PHASE4":2130,"NA":2143},{"trials":2123,"activeCount":97},[],{"trials":2125,"activeCount":97},[],{"trials":2127,"activeCount":97},[],{"trials":2129,"activeCount":97},[],{"trials":2131,"activeCount":97},[2132],{"nctId":2133,"briefTitle":2134,"status":387,"phases":2135,"primaryCompletion":2136,"completion":2137,"start":2138,"enrollment":97,"conditions":2139,"interventions":2141},"NCT03640221","Ertugliflozin Versus Hydrochlorothiazide in Reducing Sympathetic Neural Overactivity in Patients With Hypertension and Recently-diagnosed Type 2 Diabetes.",[89],"2020-05-31","2020-08-31","2018-09-01",[28,2140],"Diabetes Mellitus, Type 2",[2120,2142],"Hydrochlorothiazide 12.5mg",{"trials":2144,"activeCount":97},[],{"intervention":2142,"totalTrials":93,"cells":2146},{"EARLY_PHASE1":2147,"PHASE1":2149,"PHASE2":2151,"PHASE3":2153,"PHASE4":2155,"NA":2161},{"trials":2148,"activeCount":97},[],{"trials":2150,"activeCount":97},[],{"trials":2152,"activeCount":97},[],{"trials":2154,"activeCount":97},[],{"trials":2156,"activeCount":97},[2157],{"nctId":2133,"briefTitle":2134,"status":387,"phases":2158,"primaryCompletion":2136,"completion":2137,"start":2138,"enrollment":97,"conditions":2159,"interventions":2160},[89],[28,2140],[2120,2142],{"trials":2162,"activeCount":97},[],{"intervention":2164,"totalTrials":93,"cells":2165},"Oral anticoagulant",{"EARLY_PHASE1":2166,"PHASE1":2168,"PHASE2":2170,"PHASE3":2172,"PHASE4":2174,"NA":2187},{"trials":2167,"activeCount":97},[],{"trials":2169,"activeCount":97},[],{"trials":2171,"activeCount":97},[],{"trials":2173,"activeCount":97},[],{"trials":2175,"activeCount":97},[2176],{"nctId":2177,"briefTitle":2178,"status":1174,"phases":2179,"primaryCompletion":2180,"completion":2181,"start":2182,"enrollment":9,"conditions":2183,"interventions":2186},"NCT04907825","A Trial of Pharmacist Management of Oral Anticoagulation THerapy in the communitY for AF",[89],"2025-08-31","2026-01-31","2023-03-13",[2184,2185],"Atrial Fibrillation","Stroke",[2164],{"trials":2188,"activeCount":97},[],{"intervention":2190,"totalTrials":93,"cells":2191},"Sugar pill",{"EARLY_PHASE1":2192,"PHASE1":2194,"PHASE2":2196,"PHASE3":2198,"PHASE4":2200,"NA":2212},{"trials":2193,"activeCount":97},[],{"trials":2195,"activeCount":97},[],{"trials":2197,"activeCount":97},[],{"trials":2199,"activeCount":97},[],{"trials":2201,"activeCount":97},[2202],{"nctId":2203,"briefTitle":2204,"status":387,"phases":2205,"primaryCompletion":1406,"completion":1406,"start":1406,"enrollment":97,"conditions":2206,"interventions":2209},"NCT01112878","Oral Clonidine & Gabapentin: Improving Recovery and Pain Management After Outpatient With Major Orthopedic Surgery",[89],[2207,2208],"Shoulder Arthroscopy","Knee Arthroscopy",[2190,2210,2211],"Gabapentin","Clonidine",{"trials":2213,"activeCount":97},[],{"intervention":2210,"totalTrials":93,"cells":2215},{"EARLY_PHASE1":2216,"PHASE1":2218,"PHASE2":2220,"PHASE3":2222,"PHASE4":2224,"NA":2230},{"trials":2217,"activeCount":97},[],{"trials":2219,"activeCount":97},[],{"trials":2221,"activeCount":97},[],{"trials":2223,"activeCount":97},[],{"trials":2225,"activeCount":97},[2226],{"nctId":2203,"briefTitle":2204,"status":387,"phases":2227,"primaryCompletion":1406,"completion":1406,"start":1406,"enrollment":97,"conditions":2228,"interventions":2229},[89],[2207,2208],[2190,2210,2211],{"trials":2231,"activeCount":97},[],{"intervention":2211,"totalTrials":93,"cells":2233},{"EARLY_PHASE1":2234,"PHASE1":2236,"PHASE2":2238,"PHASE3":2240,"PHASE4":2242,"NA":2248},{"trials":2235,"activeCount":97},[],{"trials":2237,"activeCount":97},[],{"trials":2239,"activeCount":97},[],{"trials":2241,"activeCount":97},[],{"trials":2243,"activeCount":97},[2244],{"nctId":2203,"briefTitle":2204,"status":387,"phases":2245,"primaryCompletion":1406,"completion":1406,"start":1406,"enrollment":97,"conditions":2246,"interventions":2247},[89],[2207,2208],[2190,2210,2211],{"trials":2249,"activeCount":97},[],{"intervention":1153,"totalTrials":93,"cells":2251},{"EARLY_PHASE1":2252,"PHASE1":2254,"PHASE2":2256,"PHASE3":2258,"PHASE4":2260,"NA":2266},{"trials":2253,"activeCount":97},[],{"trials":2255,"activeCount":97},[],{"trials":2257,"activeCount":97},[],{"trials":2259,"activeCount":97},[],{"trials":2261,"activeCount":97},[2262],{"nctId":1145,"briefTitle":1146,"status":407,"phases":2263,"primaryCompletion":1148,"completion":1148,"start":1149,"enrollment":16,"conditions":2264,"interventions":2265},[89],[1151],[83,1153,1154],{"trials":2267,"activeCount":97},[],{"intervention":1154,"totalTrials":93,"cells":2269},{"EARLY_PHASE1":2270,"PHASE1":2272,"PHASE2":2274,"PHASE3":2276,"PHASE4":2278,"NA":2284},{"trials":2271,"activeCount":97},[],{"trials":2273,"activeCount":97},[],{"trials":2275,"activeCount":97},[],{"trials":2277,"activeCount":97},[],{"trials":2279,"activeCount":97},[2280],{"nctId":1145,"briefTitle":1146,"status":407,"phases":2281,"primaryCompletion":1148,"completion":1148,"start":1149,"enrollment":16,"conditions":2282,"interventions":2283},[89],[1151],[83,1153,1154],{"trials":2285,"activeCount":97},[],{"intervention":2287,"totalTrials":93,"cells":2288},"Medication Management",{"EARLY_PHASE1":2289,"PHASE1":2291,"PHASE2":2293,"PHASE3":2295,"PHASE4":2297,"NA":2310},{"trials":2290,"activeCount":97},[],{"trials":2292,"activeCount":97},[],{"trials":2294,"activeCount":97},[],{"trials":2296,"activeCount":97},[],{"trials":2298,"activeCount":97},[2299],{"nctId":2300,"briefTitle":2301,"status":1174,"phases":2302,"primaryCompletion":2303,"completion":2304,"start":2305,"enrollment":2306,"conditions":2307,"interventions":2309},"NCT03688100","Personalized Treatments for Depressive Symptoms in Patients With Advanced Heart Failure",[89],"2021-10-25","2022-05-06","2018-11-09",494,[21,2308],"Heart Failure",[2287],{"trials":2311,"activeCount":97},[],{"intervention":2313,"totalTrials":93,"cells":2314},"TNKase",{"EARLY_PHASE1":2315,"PHASE1":2317,"PHASE2":2319,"PHASE3":2321,"PHASE4":2323,"NA":2337},{"trials":2316,"activeCount":97},[],{"trials":2318,"activeCount":97},[],{"trials":2320,"activeCount":97},[],{"trials":2322,"activeCount":97},[],{"trials":2324,"activeCount":97},[2325],{"nctId":2326,"briefTitle":2327,"status":407,"phases":2328,"primaryCompletion":2329,"completion":2330,"start":2331,"enrollment":332,"conditions":2332,"interventions":2335},"NCT04558125","Low-Dose Tenecteplase in Covid-19 Diagnosed With Pulmonary Embolism",[89],"2021-07-10","2021-08-08","2020-09-08",[2333,2334],"Pulmonary Embolism","COVID",[2313,2336],"Enoxaparin",{"trials":2338,"activeCount":97},[],{"intervention":2336,"totalTrials":93,"cells":2340},{"EARLY_PHASE1":2341,"PHASE1":2343,"PHASE2":2345,"PHASE3":2347,"PHASE4":2349,"NA":2355},{"trials":2342,"activeCount":97},[],{"trials":2344,"activeCount":97},[],{"trials":2346,"activeCount":97},[],{"trials":2348,"activeCount":97},[],{"trials":2350,"activeCount":97},[2351],{"nctId":2326,"briefTitle":2327,"status":407,"phases":2352,"primaryCompletion":2329,"completion":2330,"start":2331,"enrollment":332,"conditions":2353,"interventions":2354},[89],[2333,2334],[2313,2336],{"trials":2356,"activeCount":97},[],{"intervention":1415,"totalTrials":93,"cells":2358},{"EARLY_PHASE1":2359,"PHASE1":2361,"PHASE2":2363,"PHASE3":2365,"PHASE4":2367,"NA":2373},{"trials":2360,"activeCount":97},[],{"trials":2362,"activeCount":97},[],{"trials":2364,"activeCount":97},[],{"trials":2366,"activeCount":97},[],{"trials":2368,"activeCount":97},[2369],{"nctId":1403,"briefTitle":1404,"status":407,"phases":2370,"primaryCompletion":1406,"completion":1406,"start":1407,"enrollment":1408,"conditions":2371,"interventions":2372},[89],[33,1410,1411,1412],[1414,1353,1415],{"trials":2374,"activeCount":97},[],{"intervention":2376,"totalTrials":93,"cells":2377},"Posaconazole Delayed Release Oral",{"EARLY_PHASE1":2378,"PHASE1":2380,"PHASE2":2382,"PHASE3":2384,"PHASE4":2386,"NA":2397},{"trials":2379,"activeCount":97},[],{"trials":2381,"activeCount":97},[],{"trials":2383,"activeCount":97},[],{"trials":2385,"activeCount":97},[],{"trials":2387,"activeCount":97},[2388],{"nctId":2389,"briefTitle":2390,"status":407,"phases":2391,"primaryCompletion":2392,"completion":2392,"start":2393,"enrollment":22,"conditions":2394,"interventions":2396},"NCT04966585","Pilot Study of Posaconazole in Crohn's Disease",[89],"2025-01-22","2022-08-17",[694,2395],"CARD9 S12N Risk Allele",[2376],{"trials":2398,"activeCount":97},[],{"intervention":2400,"totalTrials":93,"cells":2401},"liposomal bupivicaine",{"EARLY_PHASE1":2402,"PHASE1":2404,"PHASE2":2406,"PHASE3":2408,"PHASE4":2410,"NA":2421},{"trials":2403,"activeCount":97},[],{"trials":2405,"activeCount":97},[],{"trials":2407,"activeCount":97},[],{"trials":2409,"activeCount":97},[],{"trials":2411,"activeCount":97},[2412],{"nctId":2413,"briefTitle":2414,"status":1174,"phases":2415,"primaryCompletion":2416,"completion":2416,"start":2062,"enrollment":2417,"conditions":2418,"interventions":2420},"NCT04114058","A Study Comparing Fascia Iliaca Blockade vs Extracapsular Local Field Infiltration With Liposomal Bupivacaine",[89],"2020-03-17",37,[2419],"Femoro Acetabular Impingement",[2400],{"trials":2422,"activeCount":97},[],{"intervention":2424,"totalTrials":93,"cells":2425},"Bupivacaine and Dexamethasone",{"EARLY_PHASE1":2426,"PHASE1":2428,"PHASE2":2430,"PHASE3":2432,"PHASE4":2434,"NA":2446},{"trials":2427,"activeCount":97},[],{"trials":2429,"activeCount":97},[],{"trials":2431,"activeCount":97},[],{"trials":2433,"activeCount":97},[],{"trials":2435,"activeCount":97},[2436],{"nctId":2437,"briefTitle":2438,"status":264,"phases":2439,"primaryCompletion":2440,"completion":2440,"start":2441,"enrollment":2442,"conditions":2443,"interventions":2445},"NCT02005575","The Effect of Dexamethasone on the Duration and Functionality of Bupivacaine Intercostal Nerve Blockade",[89],"2015-03","2013-10",50,[2444],"Post Minimally Invasive Thorascopic Surgical Pain",[2424],{"trials":2447,"activeCount":97},[],{"intervention":2449,"totalTrials":332,"cells":2450},"Eculizumab",{"EARLY_PHASE1":2451,"PHASE1":2453,"PHASE2":2455,"PHASE3":2476,"PHASE4":2490,"NA":2492},{"trials":2452,"activeCount":97},[],{"trials":2454,"activeCount":97},[],{"trials":2456,"activeCount":97},[2457],{"nctId":2458,"briefTitle":2459,"status":407,"phases":2460,"primaryCompletion":2461,"completion":2461,"start":2462,"enrollment":332,"conditions":2463,"interventions":2475},"NCT04725812","Complement Regulation to Undo Systemic Harm in Preeclampsia",[87],"2021-12-07","2021-09-13",[2464,2465,2449,2466,2467,2468,2469,2470,2471,2472,2473,2474],"Preeclampsia","Severe Preeclampsia","HELLP","HELLP Syndrome","HELLP Syndrome Second Trimester","Pregnancy Related","AHUS","PNH","Complement Regulatory Factor Defect","Complement Abnormality","HELLP Syndrome Third Trimester",[2449],{"trials":2477,"activeCount":97},[2478],{"nctId":2479,"briefTitle":2480,"status":1174,"phases":2481,"primaryCompletion":597,"completion":2482,"start":2483,"enrollment":353,"conditions":2484,"interventions":2489},"NCT02013037","The De-novo Use of Eculizumab in Presensitized Patients Receiving Cardiac Transplantation",[88],"2020-04-30","2012-11",[2485,2486,2487,393,2488],"Antibody-mediated Rejection","Hyperacute Rejection of Cardiac Transplant","Left Ventricular Dysfunction","Heart Graft Dysfunction",[2449],{"trials":2491,"activeCount":97},[],{"trials":2493,"activeCount":97},[],{"intervention":2495,"totalTrials":93,"cells":2496},"Loperamide",{"EARLY_PHASE1":2497,"PHASE1":2499,"PHASE2":2501,"PHASE3":2503,"PHASE4":2514,"NA":2516},{"trials":2498,"activeCount":97},[],{"trials":2500,"activeCount":97},[],{"trials":2502,"activeCount":97},[],{"trials":2504,"activeCount":97},[2505],{"nctId":2506,"briefTitle":2507,"status":407,"phases":2508,"primaryCompletion":2509,"completion":2509,"start":2510,"enrollment":136,"conditions":2511,"interventions":2513},"NCT02263365","Use of Post Operative Loperamide in Colorectal Patients After Diverting Ileostomies",[88],"2016-12-31","2014-10-07",[2512],"Dehydration, Diverting Ileostomy, Loperamide",[2495],{"trials":2515,"activeCount":97},[],{"trials":2517,"activeCount":97},[],{"intervention":2519,"totalTrials":93,"cells":2520},"Heparin",{"EARLY_PHASE1":2521,"PHASE1":2523,"PHASE2":2525,"PHASE3":2527,"PHASE4":2538,"NA":2540},{"trials":2522,"activeCount":97},[],{"trials":2524,"activeCount":97},[],{"trials":2526,"activeCount":97},[],{"trials":2528,"activeCount":97},[2529],{"nctId":2530,"briefTitle":2531,"status":1174,"phases":2532,"primaryCompletion":1348,"completion":1348,"start":2533,"enrollment":2534,"conditions":2535,"interventions":2537},"NCT01976988","Prospective Study on Preoperative Versus Postoperative Venous Thromboprophylaxis in Patients Undergoing Major Colorectal Surgery",[88],"2013-09",410,[2536],"Venous Thromboembolism",[2519],{"trials":2539,"activeCount":97},[],{"trials":2541,"activeCount":97},[],{"intervention":2543,"totalTrials":93,"cells":2544},"No drug name provided by Sponsor; drug referenced as PD 0332334",{"EARLY_PHASE1":2545,"PHASE1":2547,"PHASE2":2549,"PHASE3":2551,"PHASE4":2564,"NA":2566},{"trials":2546,"activeCount":97},[],{"trials":2548,"activeCount":97},[],{"trials":2550,"activeCount":97},[],{"trials":2552,"activeCount":97},[2553],{"nctId":2554,"briefTitle":2555,"status":407,"phases":2556,"primaryCompletion":2557,"completion":1407,"start":2558,"enrollment":2559,"conditions":2560,"interventions":2562},"NCT00836069","Fixed Dose Study of PD 0332334 and Paroxetine for the Treatment of Generalized Anxiety Disorder",[88],"2009-02","2008-10",5,[2561],"Anxiety Disorders",[2543,2563],"Paroxetine",{"trials":2565,"activeCount":97},[],{"trials":2567,"activeCount":97},[],{"intervention":2563,"totalTrials":93,"cells":2569},{"EARLY_PHASE1":2570,"PHASE1":2572,"PHASE2":2574,"PHASE3":2576,"PHASE4":2582,"NA":2584},{"trials":2571,"activeCount":97},[],{"trials":2573,"activeCount":97},[],{"trials":2575,"activeCount":97},[],{"trials":2577,"activeCount":97},[2578],{"nctId":2554,"briefTitle":2555,"status":407,"phases":2579,"primaryCompletion":2557,"completion":1407,"start":2558,"enrollment":2559,"conditions":2580,"interventions":2581},[88],[2561],[2543,2563],{"trials":2583,"activeCount":97},[],{"trials":2585,"activeCount":97},[],{"intervention":2587,"totalTrials":93,"cells":2588},"Evolocumab",{"EARLY_PHASE1":2589,"PHASE1":2591,"PHASE2":2593,"PHASE3":2595,"PHASE4":2612,"NA":2614},{"trials":2590,"activeCount":97},[],{"trials":2592,"activeCount":97},[],{"trials":2594,"activeCount":97},[],{"trials":2596,"activeCount":97},[2597],{"nctId":2598,"briefTitle":2599,"status":1174,"phases":2600,"primaryCompletion":2601,"completion":2602,"start":2603,"enrollment":2604,"conditions":2605,"interventions":2608},"NCT03689946","Effect of Evolocumab on Coronary Atherosclerosis",[88],"2023-01-28","2023-05-30","2019-03-19",55,[2606,2607],"Cardiovascular Disease","Hyperlipidemia",[2587,2609,2610,2611],"Omnipaque","Metoprolol","Nitroglycerin",{"trials":2613,"activeCount":97},[],{"trials":2615,"activeCount":97},[],{"intervention":2609,"totalTrials":93,"cells":2617},{"EARLY_PHASE1":2618,"PHASE1":2620,"PHASE2":2622,"PHASE3":2624,"PHASE4":2630,"NA":2632},{"trials":2619,"activeCount":97},[],{"trials":2621,"activeCount":97},[],{"trials":2623,"activeCount":97},[],{"trials":2625,"activeCount":97},[2626],{"nctId":2598,"briefTitle":2599,"status":1174,"phases":2627,"primaryCompletion":2601,"completion":2602,"start":2603,"enrollment":2604,"conditions":2628,"interventions":2629},[88],[2606,2607],[2587,2609,2610,2611],{"trials":2631,"activeCount":97},[],{"trials":2633,"activeCount":97},[],{"intervention":2610,"totalTrials":93,"cells":2635},{"EARLY_PHASE1":2636,"PHASE1":2638,"PHASE2":2640,"PHASE3":2642,"PHASE4":2648,"NA":2650},{"trials":2637,"activeCount":97},[],{"trials":2639,"activeCount":97},[],{"trials":2641,"activeCount":97},[],{"trials":2643,"activeCount":97},[2644],{"nctId":2598,"briefTitle":2599,"status":1174,"phases":2645,"primaryCompletion":2601,"completion":2602,"start":2603,"enrollment":2604,"conditions":2646,"interventions":2647},[88],[2606,2607],[2587,2609,2610,2611],{"trials":2649,"activeCount":97},[],{"trials":2651,"activeCount":97},[],{"intervention":2611,"totalTrials":93,"cells":2653},{"EARLY_PHASE1":2654,"PHASE1":2656,"PHASE2":2658,"PHASE3":2660,"PHASE4":2666,"NA":2668},{"trials":2655,"activeCount":97},[],{"trials":2657,"activeCount":97},[],{"trials":2659,"activeCount":97},[],{"trials":2661,"activeCount":97},[2662],{"nctId":2598,"briefTitle":2599,"status":1174,"phases":2663,"primaryCompletion":2601,"completion":2602,"start":2603,"enrollment":2604,"conditions":2664,"interventions":2665},[88],[2606,2607],[2587,2609,2610,2611],{"trials":2667,"activeCount":97},[],{"trials":2669,"activeCount":97},[],{"intervention":2671,"totalTrials":1332,"cells":2672},"Rifaximin",{"EARLY_PHASE1":2673,"PHASE1":2685,"PHASE2":2687,"PHASE3":2720,"PHASE4":2722,"NA":2724},{"trials":2674,"activeCount":97},[2675],{"nctId":2676,"briefTitle":2677,"status":1174,"phases":2678,"primaryCompletion":2679,"completion":2679,"start":2680,"enrollment":1673,"conditions":2681,"interventions":2683},"NCT01638429","Role of Methane in Glycemic Control",[85],"2014-04","2012-04",[2682,304],"Diabetes",[2684,2671],"Neomycin",{"trials":2686,"activeCount":97},[],{"trials":2688,"activeCount":97},[2689,2699,2711],{"nctId":2690,"briefTitle":2691,"status":407,"phases":2692,"primaryCompletion":2693,"completion":2693,"start":2694,"enrollment":1332,"conditions":2695,"interventions":2698},"NCT03462966","Rifaximin on Visceral Hypersensitivity",[87],"2021-11-19","2018-07-01",[2696,2697],"Visceral Hypersensitivity","Irritable Bowel Syndrome",[2671],{"nctId":2700,"briefTitle":2701,"status":1174,"phases":2702,"primaryCompletion":2703,"completion":2704,"start":2705,"enrollment":2706,"conditions":2707,"interventions":2709},"NCT04557215","Efficacy and Safety of Rifaximin With NAC in IBS-D",[86,87],"2021-08-31","2022-10-30","2020-11-13",45,[2708],"Irritable Bowel Syndrome With Diarrhea",[2671,2710],"N-acetylcysteine",{"nctId":2712,"briefTitle":2713,"status":1174,"phases":2714,"primaryCompletion":2715,"completion":2715,"start":2716,"enrollment":2717,"conditions":2718,"interventions":2719},"NCT00259155","Rifaximin for the Treatment of Irritable Bowel Syndrome",[87],"2007-01","2003-07",92,[2697],[2671],{"trials":2721,"activeCount":97},[],{"trials":2723,"activeCount":97},[],{"trials":2725,"activeCount":97},[],{"intervention":2727,"totalTrials":332,"cells":2728},"Gemcitabine",{"EARLY_PHASE1":2729,"PHASE1":2731,"PHASE2":2743,"PHASE3":2757,"PHASE4":2759,"NA":2761},{"trials":2730,"activeCount":97},[],{"trials":2732,"activeCount":97},[2733],{"nctId":2734,"briefTitle":2735,"status":1174,"phases":2736,"primaryCompletion":2737,"completion":2738,"start":2739,"enrollment":429,"conditions":2740,"interventions":2741},"NCT01908478","Veliparib in Combination With Gemcitabine and Intensity Modulated Radiation Therapy in Patients With Pancreatic Cancer",[86],"2017-07-14","2020-07-06","2013-10-02",[1125],[2742,2727],"Veliparib",{"trials":2744,"activeCount":97},[2745],{"nctId":2746,"briefTitle":2747,"status":1174,"phases":2748,"primaryCompletion":2749,"completion":2750,"start":2751,"enrollment":1825,"conditions":2752,"interventions":2754},"NCT02608684","A Study of Pembrolizumab With Standard Treatment in Patients With Recurrent Platinum-resistant Ovarian Cancer",[87],"2019-05-17","2022-03-07","2016-02-08",[2753],"Ovarian Cancer",[2755,2727,2756],"Pembrolizumab","Cisplatin",{"trials":2758,"activeCount":97},[],{"trials":2760,"activeCount":97},[],{"trials":2762,"activeCount":97},[],{"intervention":2764,"totalTrials":93,"cells":2765},"SYN-010 21 mg",{"EARLY_PHASE1":2766,"PHASE1":2768,"PHASE2":2770,"PHASE3":2783,"PHASE4":2785,"NA":2787},{"trials":2767,"activeCount":97},[],{"trials":2769,"activeCount":97},[],{"trials":2771,"activeCount":97},[2772],{"nctId":2773,"briefTitle":2774,"status":407,"phases":2775,"primaryCompletion":2776,"completion":2776,"start":2777,"enrollment":2778,"conditions":2779,"interventions":2781},"NCT03763175","Efficacy and Safety of SYN-010 in IBS-C",[87],"2020-10-09","2018-12-24",59,[2780],"Irritable Bowel Syndrome With Constipation",[2764,2782],"SYN-010 42 mg",{"trials":2784,"activeCount":97},[],{"trials":2786,"activeCount":97},[],{"trials":2788,"activeCount":97},[],{"intervention":2782,"totalTrials":93,"cells":2790},{"EARLY_PHASE1":2791,"PHASE1":2793,"PHASE2":2795,"PHASE3":2801,"PHASE4":2803,"NA":2805},{"trials":2792,"activeCount":97},[],{"trials":2794,"activeCount":97},[],{"trials":2796,"activeCount":97},[2797],{"nctId":2773,"briefTitle":2774,"status":407,"phases":2798,"primaryCompletion":2776,"completion":2776,"start":2777,"enrollment":2778,"conditions":2799,"interventions":2800},[87],[2780],[2764,2782],{"trials":2802,"activeCount":97},[],{"trials":2804,"activeCount":97},[],{"trials":2806,"activeCount":97},[],{"intervention":2710,"totalTrials":93,"cells":2808},{"EARLY_PHASE1":2809,"PHASE1":2811,"PHASE2":2813,"PHASE3":2819,"PHASE4":2821,"NA":2823},{"trials":2810,"activeCount":97},[],{"trials":2812,"activeCount":97},[],{"trials":2814,"activeCount":97},[2815],{"nctId":2700,"briefTitle":2701,"status":1174,"phases":2816,"primaryCompletion":2703,"completion":2704,"start":2705,"enrollment":2706,"conditions":2817,"interventions":2818},[86,87],[2708],[2671,2710],{"trials":2820,"activeCount":97},[],{"trials":2822,"activeCount":97},[],{"trials":2824,"activeCount":97},[],{"intervention":2826,"totalTrials":93,"cells":2827},"IdeS®",{"EARLY_PHASE1":2828,"PHASE1":2830,"PHASE2":2832,"PHASE3":2844,"PHASE4":2846,"NA":2848},{"trials":2829,"activeCount":97},[],{"trials":2831,"activeCount":97},[],{"trials":2833,"activeCount":97},[2834],{"nctId":2835,"briefTitle":2836,"status":1174,"phases":2837,"primaryCompletion":2838,"completion":2838,"start":2839,"enrollment":2840,"conditions":2841,"interventions":2843},"NCT02426684","Ides in Highly Sensitized (HS) Patients Awaiting Kidney Transplantation",[86,87],"2017-11-10","2015-06-16",17,[2842],"Renal Disease",[2826],{"trials":2845,"activeCount":97},[],{"trials":2847,"activeCount":97},[],{"trials":2849,"activeCount":97},[],{"intervention":2851,"totalTrials":93,"cells":2852},"IVIG and Rituximab",{"EARLY_PHASE1":2853,"PHASE1":2855,"PHASE2":2857,"PHASE3":2868,"PHASE4":2870,"NA":2872},{"trials":2854,"activeCount":97},[],{"trials":2856,"activeCount":97},[],{"trials":2858,"activeCount":97},[2859],{"nctId":2860,"briefTitle":2861,"status":1174,"phases":2862,"primaryCompletion":2863,"completion":2863,"start":2864,"enrollment":268,"conditions":2865,"interventions":2867},"NCT00642655","Rituximab and Intravenous Immunoglobulin (IVIG) for Desensitization in Renal Transplantation",[86,87],"2007-05","2005-09",[2866],"Kidney Transplant",[2851],{"trials":2869,"activeCount":97},[],{"trials":2871,"activeCount":97},[],{"trials":2873,"activeCount":97},[],{"intervention":2875,"totalTrials":93,"cells":2876},"Temozolomide",{"EARLY_PHASE1":2877,"PHASE1":2879,"PHASE2":2881,"PHASE3":2893,"PHASE4":2895,"NA":2897},{"trials":2878,"activeCount":97},[],{"trials":2880,"activeCount":97},[],{"trials":2882,"activeCount":97},[2883],{"nctId":2884,"briefTitle":2885,"status":407,"phases":2886,"primaryCompletion":2887,"completion":2888,"start":2889,"enrollment":1673,"conditions":2890,"interventions":2892},"NCT01235793","The Addition of Temozolomide to Conditioning for Autologous Transplantation in Relapsed & Refractory CNS Lymphoma",[87],"2017-07-28","2018-04-18","2010-10-14",[2891],"B-Cell Lymphoma Originating in the CNS",[2875],{"trials":2894,"activeCount":97},[],{"trials":2896,"activeCount":97},[],{"trials":2898,"activeCount":97},[],{"intervention":2900,"totalTrials":93,"cells":2901},"TRC105",{"EARLY_PHASE1":2902,"PHASE1":2904,"PHASE2":2906,"PHASE3":2918,"PHASE4":2920,"NA":2922},{"trials":2903,"activeCount":97},[],{"trials":2905,"activeCount":97},[],{"trials":2907,"activeCount":97},[2908],{"nctId":2909,"briefTitle":2910,"status":1174,"phases":2911,"primaryCompletion":2912,"completion":2912,"start":2913,"enrollment":1673,"conditions":2914,"interventions":2915},"NCT03418324","Study of TRC105 With Abiraterone and With Enzalutamide in Prostate Cancer Patients Progressing on Therapy",[87],"2019-11-06","2018-03-05",[26],[2900,2916,2917],"Abiraterone","Enzalutamide",{"trials":2919,"activeCount":97},[],{"trials":2921,"activeCount":97},[],{"trials":2923,"activeCount":97},[],{"intervention":2916,"totalTrials":93,"cells":2925},{"EARLY_PHASE1":2926,"PHASE1":2928,"PHASE2":2930,"PHASE3":2936,"PHASE4":2938,"NA":2940},{"trials":2927,"activeCount":97},[],{"trials":2929,"activeCount":97},[],{"trials":2931,"activeCount":97},[2932],{"nctId":2909,"briefTitle":2910,"status":1174,"phases":2933,"primaryCompletion":2912,"completion":2912,"start":2913,"enrollment":1673,"conditions":2934,"interventions":2935},[87],[26],[2900,2916,2917],{"trials":2937,"activeCount":97},[],{"trials":2939,"activeCount":97},[],{"trials":2941,"activeCount":97},[],{"intervention":2917,"totalTrials":93,"cells":2943},{"EARLY_PHASE1":2944,"PHASE1":2946,"PHASE2":2948,"PHASE3":2954,"PHASE4":2956,"NA":2958},{"trials":2945,"activeCount":97},[],{"trials":2947,"activeCount":97},[],{"trials":2949,"activeCount":97},[2950],{"nctId":2909,"briefTitle":2910,"status":1174,"phases":2951,"primaryCompletion":2912,"completion":2912,"start":2913,"enrollment":1673,"conditions":2952,"interventions":2953},[87],[26],[2900,2916,2917],{"trials":2955,"activeCount":97},[],{"trials":2957,"activeCount":97},[],{"trials":2959,"activeCount":97},[],{"intervention":2961,"totalTrials":93,"cells":2962},"Atorvastatin",{"EARLY_PHASE1":2963,"PHASE1":2965,"PHASE2":2967,"PHASE3":2980,"PHASE4":2982,"NA":2984},{"trials":2964,"activeCount":97},[],{"trials":2966,"activeCount":97},[],{"trials":2968,"activeCount":97},[2969],{"nctId":2970,"briefTitle":2971,"status":407,"phases":2972,"primaryCompletion":2973,"completion":2973,"start":2974,"enrollment":332,"conditions":2975,"interventions":2979},"NCT02674204","STOP Heart Disease in Breast Cancer Survivors Trial",[87],"2018-05-25","2016-05-05",[15,2976,2977,2978],"Heart Disease","Cardiotoxicity","Myocardial Dysfunction",[2961],{"trials":2981,"activeCount":97},[],{"trials":2983,"activeCount":97},[],{"trials":2985,"activeCount":97},[],{"intervention":2987,"totalTrials":93,"cells":2988},"Lapatinib",{"EARLY_PHASE1":2989,"PHASE1":2991,"PHASE2":2993,"PHASE3":3005,"PHASE4":3007,"NA":3009},{"trials":2990,"activeCount":97},[],{"trials":2992,"activeCount":97},[],{"trials":2994,"activeCount":97},[2995],{"nctId":2996,"briefTitle":2997,"status":1174,"phases":2998,"primaryCompletion":2999,"completion":2999,"start":3000,"enrollment":31,"conditions":3001,"interventions":3004},"NCT00939523","Targeted Therapy With Lapatinib in Patients With Recurrent Pituitary Tumors Resistant to Standard Therapy",[87],"2018-12","2009-07",[3002,3003],"Pituitary Adenomas","Prolactinomas",[2987],{"trials":3006,"activeCount":97},[],{"trials":3008,"activeCount":97},[],{"trials":3010,"activeCount":97},[],{"intervention":446,"totalTrials":93,"cells":3012},{"EARLY_PHASE1":3013,"PHASE1":3015,"PHASE2":3017,"PHASE3":3023,"PHASE4":3025,"NA":3027},{"trials":3014,"activeCount":97},[],{"trials":3016,"activeCount":97},[],{"trials":3018,"activeCount":97},[3019],{"nctId":438,"briefTitle":439,"status":387,"phases":3020,"primaryCompletion":441,"completion":442,"start":441,"enrollment":97,"conditions":3021,"interventions":3022},[87],[15,444],[446,400,447],{"trials":3024,"activeCount":97},[],{"trials":3026,"activeCount":97},[],{"trials":3028,"activeCount":97},[],{"intervention":447,"totalTrials":93,"cells":3030},{"EARLY_PHASE1":3031,"PHASE1":3033,"PHASE2":3035,"PHASE3":3041,"PHASE4":3043,"NA":3045},{"trials":3032,"activeCount":97},[],{"trials":3034,"activeCount":97},[],{"trials":3036,"activeCount":97},[3037],{"nctId":438,"briefTitle":439,"status":387,"phases":3038,"primaryCompletion":441,"completion":442,"start":441,"enrollment":97,"conditions":3039,"interventions":3040},[87],[15,444],[446,400,447],{"trials":3042,"activeCount":97},[],{"trials":3044,"activeCount":97},[],{"trials":3046,"activeCount":97},[],{"intervention":3048,"totalTrials":93,"cells":3049},"Tofacitinib 10 mg",{"EARLY_PHASE1":3050,"PHASE1":3052,"PHASE2":3054,"PHASE3":3069,"PHASE4":3071,"NA":3073},{"trials":3051,"activeCount":97},[],{"trials":3053,"activeCount":97},[],{"trials":3055,"activeCount":97},[3056],{"nctId":3057,"briefTitle":3058,"status":407,"phases":3059,"primaryCompletion":3060,"completion":3061,"start":3062,"enrollment":3063,"conditions":3064,"interventions":3068},"NCT04580277","Tofacitinib For Treatment Of Chronic Pouchitis",[87],"2022-12-01","2023-05-15","2021-01-25",6,[3065,3066,3067],"Pouchitis","Ileal Pouchitis","Ileal Pouch",[3048],{"trials":3070,"activeCount":97},[],{"trials":3072,"activeCount":97},[],{"trials":3074,"activeCount":97},[],{"intervention":3076,"totalTrials":93,"cells":3077},"Ixabepilone",{"EARLY_PHASE1":3078,"PHASE1":3080,"PHASE2":3082,"PHASE3":3101,"PHASE4":3103,"NA":3105},{"trials":3079,"activeCount":97},[],{"trials":3081,"activeCount":97},[],{"trials":3083,"activeCount":97},[3084],{"nctId":3085,"briefTitle":3086,"status":407,"phases":3087,"primaryCompletion":3088,"completion":3089,"start":3090,"enrollment":1673,"conditions":3091,"interventions":3100},"NCT00672009","A Study of Ixabepilone Before Surgery for High-Risk Localized Prostate Cancer",[87],"2011-04","2012-08","2008-04",[3092,3093,3094,3095,3096,3097,3098,3099],"Prostatic Diseases","Genital Neoplasms, Male","Urogenital Neoplasms","Genital Diseases, Male","Adenocarcinoma","Prostatic Neoplasms","Neoplasms, Glandular and Epithelial","Carcinoma",[3076],{"trials":3102,"activeCount":97},[],{"trials":3104,"activeCount":97},[],{"trials":3106,"activeCount":97},[],{"intervention":3108,"totalTrials":93,"cells":3109},"Dexamethasone 4mg",{"EARLY_PHASE1":3110,"PHASE1":3112,"PHASE2":3114,"PHASE3":3125,"PHASE4":3127,"NA":3129},{"trials":3111,"activeCount":97},[],{"trials":3113,"activeCount":97},[],{"trials":3115,"activeCount":97},[3116],{"nctId":3117,"briefTitle":3118,"status":407,"phases":3119,"primaryCompletion":3120,"completion":3120,"start":3121,"enrollment":34,"conditions":3122,"interventions":3124},"NCT04066647","Detection of miRNAs in HPA Axis Function in Healthy Subjects",[86,87],"2019-07-24","2019-05-09",[3123],"Dexamethasone Effect on miRNA Profile in Healthy Humans",[3108],{"trials":3126,"activeCount":97},[],{"trials":3128,"activeCount":97},[],{"trials":3130,"activeCount":97},[],{"intervention":2755,"totalTrials":93,"cells":3132},{"EARLY_PHASE1":3133,"PHASE1":3135,"PHASE2":3137,"PHASE3":3143,"PHASE4":3145,"NA":3147},{"trials":3134,"activeCount":97},[],{"trials":3136,"activeCount":97},[],{"trials":3138,"activeCount":97},[3139],{"nctId":2746,"briefTitle":2747,"status":1174,"phases":3140,"primaryCompletion":2749,"completion":2750,"start":2751,"enrollment":1825,"conditions":3141,"interventions":3142},[87],[2753],[2755,2727,2756],{"trials":3144,"activeCount":97},[],{"trials":3146,"activeCount":97},[],{"trials":3148,"activeCount":97},[],{"intervention":2756,"totalTrials":93,"cells":3150},{"EARLY_PHASE1":3151,"PHASE1":3153,"PHASE2":3155,"PHASE3":3161,"PHASE4":3163,"NA":3165},{"trials":3152,"activeCount":97},[],{"trials":3154,"activeCount":97},[],{"trials":3156,"activeCount":97},[3157],{"nctId":2746,"briefTitle":2747,"status":1174,"phases":3158,"primaryCompletion":2749,"completion":2750,"start":2751,"enrollment":1825,"conditions":3159,"interventions":3160},[87],[2753],[2755,2727,2756],{"trials":3162,"activeCount":97},[],{"trials":3164,"activeCount":97},[],{"trials":3166,"activeCount":97},[],{"intervention":3168,"totalTrials":93,"cells":3169},"Dendritic Cell Immunotherapy",{"EARLY_PHASE1":3170,"PHASE1":3172,"PHASE2":3174,"PHASE3":3185,"PHASE4":3187,"NA":3189},{"trials":3171,"activeCount":97},[],{"trials":3173,"activeCount":97},[],{"trials":3175,"activeCount":97},[3176],{"nctId":3177,"briefTitle":3178,"status":1174,"phases":3179,"primaryCompletion":3180,"completion":3180,"start":3181,"enrollment":2442,"conditions":3182,"interventions":3184},"NCT00576537","Tumor Lysate Pulsed Dendritic Cell Immunotherapy for Patients With Brain Tumors",[87],"2011-10","2001-03",[3183],"Glioblastoma",[3168],{"trials":3186,"activeCount":97},[],{"trials":3188,"activeCount":97},[],{"trials":3190,"activeCount":97},[],{"intervention":3192,"totalTrials":93,"cells":3193},"Tocilizumab",{"EARLY_PHASE1":3194,"PHASE1":3196,"PHASE2":3198,"PHASE3":3210,"PHASE4":3212,"NA":3214},{"trials":3195,"activeCount":97},[],{"trials":3197,"activeCount":97},[],{"trials":3199,"activeCount":97},[3200],{"nctId":3201,"briefTitle":3202,"status":1174,"phases":3203,"primaryCompletion":3204,"completion":1348,"start":3205,"enrollment":22,"conditions":3206,"interventions":3208},"NCT01594424","A Safety Study of Tocilizumab to Improve Transplant Rates in Highly Sensitized Patients Awaiting Kidney Transplantation",[86,87],"2014-11","2012-06",[3207],"End Stage Renal Disease (ESRD)",[3192,3209],"Intravenous Immunoglobulin",{"trials":3211,"activeCount":97},[],{"trials":3213,"activeCount":97},[],{"trials":3215,"activeCount":97},[],{"intervention":3209,"totalTrials":93,"cells":3217},{"EARLY_PHASE1":3218,"PHASE1":3220,"PHASE2":3222,"PHASE3":3228,"PHASE4":3230,"NA":3232},{"trials":3219,"activeCount":97},[],{"trials":3221,"activeCount":97},[],{"trials":3223,"activeCount":97},[3224],{"nctId":3201,"briefTitle":3202,"status":1174,"phases":3225,"primaryCompletion":3204,"completion":1348,"start":3205,"enrollment":22,"conditions":3226,"interventions":3227},[86,87],[3207],[3192,3209],{"trials":3229,"activeCount":97},[],{"trials":3231,"activeCount":97},[],{"trials":3233,"activeCount":97},[],{"intervention":3235,"totalTrials":93,"cells":3236},"17beta Estradiol",{"EARLY_PHASE1":3237,"PHASE1":3239,"PHASE2":3241,"PHASE3":3257,"PHASE4":3259,"NA":3261},{"trials":3238,"activeCount":97},[],{"trials":3240,"activeCount":97},[],{"trials":3242,"activeCount":97},[3243],{"nctId":3244,"briefTitle":3245,"status":1174,"phases":3246,"primaryCompletion":3247,"completion":3247,"start":3248,"enrollment":3249,"conditions":3250,"interventions":3254},"NCT03018366","Atherosclerosis, Immune Mediated Inflammation and Hypoestrogenemia in Young Women",[87],"2023-02-01","2017-01-01",29,[3251,3252,3253,1456],"Estrogen Deficiency","Cardiovascular Disease (CVD)","Functional Hypothalamic Amenorrhea",[3235,3255,3256],"Transdermal placebo patch","Progesterone",{"trials":3258,"activeCount":97},[],{"trials":3260,"activeCount":97},[],{"trials":3262,"activeCount":97},[],{"intervention":3255,"totalTrials":93,"cells":3264},{"EARLY_PHASE1":3265,"PHASE1":3267,"PHASE2":3269,"PHASE3":3275,"PHASE4":3277,"NA":3279},{"trials":3266,"activeCount":97},[],{"trials":3268,"activeCount":97},[],{"trials":3270,"activeCount":97},[3271],{"nctId":3244,"briefTitle":3245,"status":1174,"phases":3272,"primaryCompletion":3247,"completion":3247,"start":3248,"enrollment":3249,"conditions":3273,"interventions":3274},[87],[3251,3252,3253,1456],[3235,3255,3256],{"trials":3276,"activeCount":97},[],{"trials":3278,"activeCount":97},[],{"trials":3280,"activeCount":97},[],{"intervention":3256,"totalTrials":93,"cells":3282},{"EARLY_PHASE1":3283,"PHASE1":3285,"PHASE2":3287,"PHASE3":3293,"PHASE4":3295,"NA":3297},{"trials":3284,"activeCount":97},[],{"trials":3286,"activeCount":97},[],{"trials":3288,"activeCount":97},[3289],{"nctId":3244,"briefTitle":3245,"status":1174,"phases":3290,"primaryCompletion":3247,"completion":3247,"start":3248,"enrollment":3249,"conditions":3291,"interventions":3292},[87],[3251,3252,3253,1456],[3235,3255,3256],{"trials":3294,"activeCount":97},[],{"trials":3296,"activeCount":97},[],{"trials":3298,"activeCount":97},[],{"intervention":3300,"totalTrials":93,"cells":3301},"Mirabegron 50 MG",{"EARLY_PHASE1":3302,"PHASE1":3304,"PHASE2":3306,"PHASE3":3320,"PHASE4":3322,"NA":3324},{"trials":3303,"activeCount":97},[],{"trials":3305,"activeCount":97},[],{"trials":3307,"activeCount":97},[3308],{"nctId":3309,"briefTitle":3310,"status":1174,"phases":3311,"primaryCompletion":3312,"completion":428,"start":3313,"enrollment":268,"conditions":3314,"interventions":3318},"NCT06133075","Using Mirabegron to Increase BP in Patients With POTS",[87],"2025-05-20","2023-12-22",[3315,3316,3317],"Postural Orthostatic Tachycardia Syndrome","Chronic Orthostatic Intolerance","Syncope",[3300,3319],"Mirabegron 25 MG",{"trials":3321,"activeCount":97},[],{"trials":3323,"activeCount":97},[],{"trials":3325,"activeCount":97},[],{"intervention":3319,"totalTrials":93,"cells":3327},{"EARLY_PHASE1":3328,"PHASE1":3330,"PHASE2":3332,"PHASE3":3338,"PHASE4":3340,"NA":3342},{"trials":3329,"activeCount":97},[],{"trials":3331,"activeCount":97},[],{"trials":3333,"activeCount":97},[3334],{"nctId":3309,"briefTitle":3310,"status":1174,"phases":3335,"primaryCompletion":3312,"completion":428,"start":3313,"enrollment":268,"conditions":3336,"interventions":3337},[87],[3315,3316,3317],[3300,3319],{"trials":3339,"activeCount":97},[],{"trials":3341,"activeCount":97},[],{"trials":3343,"activeCount":97},[],{"intervention":3345,"totalTrials":93,"cells":3346},"Berinert",{"EARLY_PHASE1":3347,"PHASE1":3349,"PHASE2":3351,"PHASE3":3363,"PHASE4":3365,"NA":3367},{"trials":3348,"activeCount":97},[],{"trials":3350,"activeCount":97},[],{"trials":3352,"activeCount":97},[3353],{"nctId":3354,"briefTitle":3355,"status":1174,"phases":3356,"primaryCompletion":3357,"completion":3358,"start":3359,"enrollment":2706,"conditions":3360,"interventions":3362},"NCT04696146","Berinert (C1INH) vs Placebo for DGF\u002FIRI",[86,87],"2022-07-31","2024-10-31","2021-03-03",[2115,3361],"Chronic Kidney Diseases",[3345],{"trials":3364,"activeCount":97},[],{"trials":3366,"activeCount":97},[],{"trials":3368,"activeCount":97},[],{"intervention":3370,"totalTrials":93,"cells":3371},"Pasireotide",{"EARLY_PHASE1":3372,"PHASE1":3374,"PHASE2":3376,"PHASE3":3386,"PHASE4":3388,"NA":3390},{"trials":3373,"activeCount":97},[],{"trials":3375,"activeCount":97},[],{"trials":3377,"activeCount":97},[3378],{"nctId":3379,"briefTitle":3380,"status":387,"phases":3381,"primaryCompletion":2999,"completion":1671,"start":3382,"enrollment":97,"conditions":3383,"interventions":3385},"NCT02780882","SOM230 Ectopic ACTH-producing Tumors",[87],"2015-12",[3384],"Ectopic ACTH Syndrome",[3370],{"trials":3387,"activeCount":97},[],{"trials":3389,"activeCount":97},[],{"trials":3391,"activeCount":97},[],{"intervention":3393,"totalTrials":93,"cells":3394},"C1 Esterase Inhibitor",{"EARLY_PHASE1":3395,"PHASE1":3397,"PHASE2":3399,"PHASE3":3413,"PHASE4":3415,"NA":3417},{"trials":3396,"activeCount":97},[],{"trials":3398,"activeCount":97},[],{"trials":3400,"activeCount":97},[3401],{"nctId":3402,"briefTitle":3403,"status":1174,"phases":3404,"primaryCompletion":3405,"completion":3405,"start":3406,"enrollment":3407,"conditions":3408,"interventions":3412},"NCT02134314","C1INH Inhibitor Preoperative and Post Kidney Transplant to Prevent DGF & IRI",[86,87],"2017-03-13","2014-09",70,[2115,3409,3410,3411],"Kidney Failure","Delayed Graft Function","Ischemic Reperfusion Injury",[3393],{"trials":3414,"activeCount":97},[],{"trials":3416,"activeCount":97},[],{"trials":3418,"activeCount":97},[],{"intervention":3420,"totalTrials":93,"cells":3421},"Remifentanil TIVA",{"EARLY_PHASE1":3422,"PHASE1":3424,"PHASE2":3426,"PHASE3":3444,"PHASE4":3446,"NA":3448},{"trials":3423,"activeCount":97},[],{"trials":3425,"activeCount":97},[],{"trials":3427,"activeCount":97},[3428],{"nctId":3429,"briefTitle":3430,"status":407,"phases":3431,"primaryCompletion":3432,"completion":3432,"start":3433,"enrollment":16,"conditions":3434,"interventions":3441},"NCT06096181","Propofol + Remifentanil vs. Propofol + Dexmedetomidine in Adolescent Idiopathic Scoliosis Patients Having Spine Surgery",[87],"2024-12-24","2023-12-20",[3435,3436,3437,3438,3439,3440],"Adolescent Idiopathic Scoliosis","Multimodal Analgesia","Opioid Induced Hyperalgesia","Remifentanil","Dexmedetomidine","Posterior Spinal Fusion",[3420,3442,3443],"Dexmedetomidine TIVA","Propofol TIVA",{"trials":3445,"activeCount":97},[],{"trials":3447,"activeCount":97},[],{"trials":3449,"activeCount":97},[],{"intervention":3442,"totalTrials":93,"cells":3451},{"EARLY_PHASE1":3452,"PHASE1":3454,"PHASE2":3456,"PHASE3":3462,"PHASE4":3464,"NA":3466},{"trials":3453,"activeCount":97},[],{"trials":3455,"activeCount":97},[],{"trials":3457,"activeCount":97},[3458],{"nctId":3429,"briefTitle":3430,"status":407,"phases":3459,"primaryCompletion":3432,"completion":3432,"start":3433,"enrollment":16,"conditions":3460,"interventions":3461},[87],[3435,3436,3437,3438,3439,3440],[3420,3442,3443],{"trials":3463,"activeCount":97},[],{"trials":3465,"activeCount":97},[],{"trials":3467,"activeCount":97},[],{"intervention":3443,"totalTrials":93,"cells":3469},{"EARLY_PHASE1":3470,"PHASE1":3472,"PHASE2":3474,"PHASE3":3480,"PHASE4":3482,"NA":3484},{"trials":3471,"activeCount":97},[],{"trials":3473,"activeCount":97},[],{"trials":3475,"activeCount":97},[3476],{"nctId":3429,"briefTitle":3430,"status":407,"phases":3477,"primaryCompletion":3432,"completion":3432,"start":3433,"enrollment":16,"conditions":3478,"interventions":3479},[87],[3435,3436,3437,3438,3439,3440],[3420,3442,3443],{"trials":3481,"activeCount":97},[],{"trials":3483,"activeCount":97},[],{"trials":3485,"activeCount":97},[],{"intervention":3487,"totalTrials":93,"cells":3488},"Propranolol",{"EARLY_PHASE1":3489,"PHASE1":3491,"PHASE2":3493,"PHASE3":3503,"PHASE4":3505,"NA":3507},{"trials":3490,"activeCount":97},[],{"trials":3492,"activeCount":97},[],{"trials":3494,"activeCount":97},[3495],{"nctId":3496,"briefTitle":3497,"status":407,"phases":3498,"primaryCompletion":3499,"completion":3499,"start":1613,"enrollment":22,"conditions":3500,"interventions":3502},"NCT01202110","Early Propranolol After Traumatic Brain Injury: Phase II",[87],"2015-02",[3501],"Traumatic Brain Injury",[3487],{"trials":3504,"activeCount":97},[],{"trials":3506,"activeCount":97},[],{"trials":3508,"activeCount":97},[],{"intervention":3510,"totalTrials":93,"cells":3511},"Clazakizumab",{"EARLY_PHASE1":3512,"PHASE1":3514,"PHASE2":3516,"PHASE3":3527,"PHASE4":3529,"NA":3531},{"trials":3513,"activeCount":97},[],{"trials":3515,"activeCount":97},[],{"trials":3517,"activeCount":97},[3518],{"nctId":3519,"briefTitle":3520,"status":1174,"phases":3521,"primaryCompletion":3522,"completion":3522,"start":3523,"enrollment":2840,"conditions":3524,"interventions":3526},"NCT04348500","Clazakizumab (Anti-Interleukin 6 (IL-6) Monoclonal) Compared to Placebo for Coronavirus Disease 2019 (COVID-19)",[87],"2020-09-30","2020-04-28",[3525],"COVID-19",[3510],{"trials":3528,"activeCount":97},[],{"trials":3530,"activeCount":97},[],{"trials":3532,"activeCount":97},[],{"intervention":3534,"totalTrials":93,"cells":3535},"Allogeneic Derived Cells",{"EARLY_PHASE1":3536,"PHASE1":3538,"PHASE2":3540,"PHASE3":3554,"PHASE4":3556,"NA":3558},{"trials":3537,"activeCount":97},[],{"trials":3539,"activeCount":97},[],{"trials":3541,"activeCount":97},[3542],{"nctId":3543,"briefTitle":3544,"status":1174,"phases":3545,"primaryCompletion":3546,"completion":3547,"start":3548,"enrollment":3549,"conditions":3550,"interventions":3553},"NCT02941705","Regression of Fibrosis & Reversal of Diastolic Dysfunction in HFpEF Patients Treated With Allogeneic CDCs",[87],"2023-04-28","2023-05-31","2017-07-12",27,[3551,3552],"Congestive Heart Failure","Heart Failure, Diastolic",[3534],{"trials":3555,"activeCount":97},[],{"trials":3557,"activeCount":97},[],{"trials":3559,"activeCount":97},[],{"intervention":3561,"totalTrials":93,"cells":3562},"Pravastatin Pill",{"EARLY_PHASE1":3563,"PHASE1":3565,"PHASE2":3567,"PHASE3":3580,"PHASE4":3582,"NA":3584},{"trials":3564,"activeCount":97},[],{"trials":3566,"activeCount":97},[],{"trials":3568,"activeCount":97},[3569],{"nctId":3570,"briefTitle":3571,"status":407,"phases":3572,"primaryCompletion":3573,"completion":3574,"start":3575,"enrollment":93,"conditions":3576,"interventions":3579},"NCT03219372","Pravastatin Intervention to Delay Hepatocellular Carcinoma Recurrence",[87],"2018-12-04","2019-03-05","2018-09-27",[3577,3578],"Hepatocellular Carcinoma","Liver Cirrhoses",[3561],{"trials":3581,"activeCount":97},[],{"trials":3583,"activeCount":97},[],{"trials":3585,"activeCount":97},[],{"intervention":3587,"totalTrials":93,"cells":3588},"Intracoronary Transplantation of Bone Marrow Stem Cells",{"EARLY_PHASE1":3589,"PHASE1":3591,"PHASE2":3602,"PHASE3":3604,"PHASE4":3606,"NA":3608},{"trials":3590,"activeCount":97},[],{"trials":3592,"activeCount":97},[3593],{"nctId":3594,"briefTitle":3595,"status":1174,"phases":3596,"primaryCompletion":3597,"completion":3597,"start":3598,"enrollment":3549,"conditions":3599,"interventions":3601},"NCT00874354","Randomized Evaluation of Intracoronary Transplantation of Bone Marrow Stem Cells in Myocardial Infarction",[86],"2013-06","2005-07",[3600],"Myocardial Infarction",[3587],{"trials":3603,"activeCount":97},[],{"trials":3605,"activeCount":97},[],{"trials":3607,"activeCount":97},[],{"trials":3609,"activeCount":97},[],{"intervention":3611,"totalTrials":93,"cells":3612},"Dendritic Cell Vaccine in combination with Imiquimod cream",{"EARLY_PHASE1":3613,"PHASE1":3615,"PHASE2":3628,"PHASE3":3630,"PHASE4":3632,"NA":3634},{"trials":3614,"activeCount":97},[],{"trials":3616,"activeCount":97},[3617],{"nctId":3618,"briefTitle":3619,"status":1174,"phases":3620,"primaryCompletion":3621,"completion":3622,"start":3623,"enrollment":3624,"conditions":3625,"interventions":3627},"NCT01792505","Dendritic Cell Vaccine With Imiquimod for Patients With Malignant Glioma",[86],"2014-11-14","2016-10","2009-10",71,[3626],"Malignant Glioma",[3611],{"trials":3629,"activeCount":97},[],{"trials":3631,"activeCount":97},[],{"trials":3633,"activeCount":97},[],{"trials":3635,"activeCount":97},[],{"intervention":3637,"totalTrials":93,"cells":3638},"autologous dendritic cells",{"EARLY_PHASE1":3639,"PHASE1":3641,"PHASE2":3651,"PHASE3":3653,"PHASE4":3655,"NA":3657},{"trials":3640,"activeCount":97},[],{"trials":3642,"activeCount":97},[3643],{"nctId":3644,"briefTitle":3645,"status":1174,"phases":3646,"primaryCompletion":1472,"completion":2680,"start":2863,"enrollment":3647,"conditions":3648,"interventions":3650},"NCT00576641","Immunotherapy for Patients With Brain Stem Glioma and Glioblastoma",[86],22,[3649,3183],"Brain Stem Glioma",[3637],{"trials":3652,"activeCount":97},[],{"trials":3654,"activeCount":97},[],{"trials":3656,"activeCount":97},[],{"trials":3658,"activeCount":97},[],{"intervention":3660,"totalTrials":93,"cells":3661},"Tadalafil and Sildenafil",{"EARLY_PHASE1":3662,"PHASE1":3664,"PHASE2":3673,"PHASE3":3675,"PHASE4":3677,"NA":3679},{"trials":3663,"activeCount":97},[],{"trials":3665,"activeCount":97},[3666],{"nctId":3667,"briefTitle":3668,"status":1174,"phases":3669,"primaryCompletion":3670,"start":1672,"enrollment":19,"conditions":3671,"interventions":3672},"NCT01580501","PDE Inhibitors in DMD Study (Acute Dosing Study)",[86],"2013-03",[1442],[3660],{"trials":3674,"activeCount":97},[],{"trials":3676,"activeCount":97},[],{"trials":3678,"activeCount":97},[],{"trials":3680,"activeCount":97},[],{"intervention":3682,"totalTrials":93,"cells":3683},"Dendritic cell vaccination, in addition to standard temozolomide chemotherapy and involved field radiation therapy",{"EARLY_PHASE1":3684,"PHASE1":3686,"PHASE2":3701,"PHASE3":3703,"PHASE4":3705,"NA":3707},{"trials":3685,"activeCount":97},[],{"trials":3687,"activeCount":97},[3688],{"nctId":3689,"briefTitle":3690,"status":1174,"phases":3691,"primaryCompletion":3692,"completion":2329,"start":3693,"enrollment":3694,"conditions":3695,"interventions":3699},"NCT02010606","Phase I Study of a Dendritic Cell Vaccine for Patients With Either Newly Diagnosed or Recurrent Glioblastoma",[86],"2019-01-23","2014-01-08",39,[3183,3696,413,3697,3698],"Glioblastoma Multiforme","Astrocytoma","Brain Tumor",[3682,3700],"Dendritic cell vaccination, with optional bevacizumab treatment for patients previously treated with bevacizumab",{"trials":3702,"activeCount":97},[],{"trials":3704,"activeCount":97},[],{"trials":3706,"activeCount":97},[],{"trials":3708,"activeCount":97},[],{"intervention":3700,"totalTrials":93,"cells":3710},{"EARLY_PHASE1":3711,"PHASE1":3713,"PHASE2":3719,"PHASE3":3721,"PHASE4":3723,"NA":3725},{"trials":3712,"activeCount":97},[],{"trials":3714,"activeCount":97},[3715],{"nctId":3689,"briefTitle":3690,"status":1174,"phases":3716,"primaryCompletion":3692,"completion":2329,"start":3693,"enrollment":3694,"conditions":3717,"interventions":3718},[86],[3183,3696,413,3697,3698],[3682,3700],{"trials":3720,"activeCount":97},[],{"trials":3722,"activeCount":97},[],{"trials":3724,"activeCount":97},[],{"trials":3726,"activeCount":97},[],{"intervention":2742,"totalTrials":93,"cells":3728},{"EARLY_PHASE1":3729,"PHASE1":3731,"PHASE2":3737,"PHASE3":3739,"PHASE4":3741,"NA":3743},{"trials":3730,"activeCount":97},[],{"trials":3732,"activeCount":97},[3733],{"nctId":2734,"briefTitle":2735,"status":1174,"phases":3734,"primaryCompletion":2737,"completion":2738,"start":2739,"enrollment":429,"conditions":3735,"interventions":3736},[86],[1125],[2742,2727],{"trials":3738,"activeCount":97},[],{"trials":3740,"activeCount":97},[],{"trials":3742,"activeCount":97},[],{"trials":3744,"activeCount":97},[],{"intervention":3746,"totalTrials":93,"cells":3747},"Autologous stem cell",{"EARLY_PHASE1":3748,"PHASE1":3750,"PHASE2":3764,"PHASE3":3766,"PHASE4":3768,"NA":3770},{"trials":3749,"activeCount":97},[],{"trials":3751,"activeCount":97},[3752],{"nctId":3753,"briefTitle":3754,"status":1174,"phases":3755,"primaryCompletion":3756,"completion":3757,"start":3758,"enrollment":3759,"conditions":3760,"interventions":3763},"NCT00893360","CArdiosphere-Derived aUtologous Stem CElls to Reverse ventricUlar dySfunction",[86],"2011-08","2012-02","2009-05",31,[3761,3762],"Recent Myocardial Infarction","Ventricular Dysfunction",[3746,3746],{"trials":3765,"activeCount":97},[],{"trials":3767,"activeCount":97},[],{"trials":3769,"activeCount":97},[],{"trials":3771,"activeCount":97},[],{"intervention":3773,"totalTrials":93,"cells":3774},"EUS enhanced with contrast to evaluate pancreas",{"EARLY_PHASE1":3775,"PHASE1":3777,"PHASE2":3790,"PHASE3":3792,"PHASE4":3794,"NA":3796},{"trials":3776,"activeCount":97},[],{"trials":3778,"activeCount":97},[3779],{"nctId":3780,"briefTitle":3781,"status":264,"phases":3782,"primaryCompletion":44,"completion":44,"start":3783,"enrollment":3784,"conditions":3785,"interventions":3789},"NCT04324294","Contrast Enhanced Endoscopic Ultrasound in Pancreas Lesions",[86],"2020-02-26",200,[3786,3787,3788],"Pancreatitis","Pancreas Cancer","Pancreas Cyst",[3773],{"trials":3791,"activeCount":97},[],{"trials":3793,"activeCount":97},[],{"trials":3795,"activeCount":97},[],{"trials":3797,"activeCount":97},[],{"intervention":3799,"totalTrials":93,"cells":3800},"FemLife Gel",{"EARLY_PHASE1":3801,"PHASE1":3803,"PHASE2":3813,"PHASE3":3815,"PHASE4":3817,"NA":3819},{"trials":3802,"activeCount":97},[],{"trials":3804,"activeCount":97},[3805],{"nctId":3806,"briefTitle":3807,"status":407,"phases":3808,"primaryCompletion":3809,"completion":3809,"start":2863,"enrollment":22,"conditions":3810,"interventions":3812},"NCT00572377","Alprostadil (FemLife Gel) in the Treatment of Female Sexual Arousal Disorder",[86],"2008-03",[3811],"Female Sexual Arousal Disorder",[3799],{"trials":3814,"activeCount":97},[],{"trials":3816,"activeCount":97},[],{"trials":3818,"activeCount":97},[],{"trials":3820,"activeCount":97},[],{"intervention":3822,"totalTrials":93,"cells":3823},"Endomyocardial injections of allogeneic Human CSps",{"EARLY_PHASE1":3824,"PHASE1":3826,"PHASE2":3838,"PHASE3":3840,"PHASE4":3842,"NA":3844},{"trials":3825,"activeCount":97},[],{"trials":3827,"activeCount":97},[3828],{"nctId":3829,"briefTitle":3830,"status":387,"phases":3831,"primaryCompletion":3832,"completion":3832,"start":1367,"enrollment":97,"conditions":3833,"interventions":3836},"NCT01496209","REgenerative CardiOsphere iNjection to STRengthen dysfUnCTional Hearts",[86],"2017-09",[3834,3835],"Ischemic Cardiomyopathy","Chronic Ischemic Cardiomyopathy",[3822,3837],"Endomyocardial injections of vehicle only.",{"trials":3839,"activeCount":97},[],{"trials":3841,"activeCount":97},[],{"trials":3843,"activeCount":97},[],{"trials":3845,"activeCount":97},[],{"intervention":3837,"totalTrials":93,"cells":3847},{"EARLY_PHASE1":3848,"PHASE1":3850,"PHASE2":3856,"PHASE3":3858,"PHASE4":3860,"NA":3862},{"trials":3849,"activeCount":97},[],{"trials":3851,"activeCount":97},[3852],{"nctId":3829,"briefTitle":3830,"status":387,"phases":3853,"primaryCompletion":3832,"completion":3832,"start":1367,"enrollment":97,"conditions":3854,"interventions":3855},[86],[3834,3835],[3822,3837],{"trials":3857,"activeCount":97},[],{"trials":3859,"activeCount":97},[],{"trials":3861,"activeCount":97},[],{"trials":3863,"activeCount":97},[],{"intervention":1458,"totalTrials":93,"cells":3865},{"EARLY_PHASE1":3866,"PHASE1":3868,"PHASE2":3874,"PHASE3":3876,"PHASE4":3878,"NA":3880},{"trials":3867,"activeCount":97},[],{"trials":3869,"activeCount":97},[3870],{"nctId":1448,"briefTitle":1449,"status":407,"phases":3871,"primaryCompletion":1451,"completion":1452,"start":1453,"enrollment":374,"conditions":3872,"interventions":3873},[86],[1455,1456],[1458,1459,1460],{"trials":3875,"activeCount":97},[],{"trials":3877,"activeCount":97},[],{"trials":3879,"activeCount":97},[],{"trials":3881,"activeCount":97},[],{"intervention":1459,"totalTrials":93,"cells":3883},{"EARLY_PHASE1":3884,"PHASE1":3886,"PHASE2":3892,"PHASE3":3894,"PHASE4":3896,"NA":3898},{"trials":3885,"activeCount":97},[],{"trials":3887,"activeCount":97},[3888],{"nctId":1448,"briefTitle":1449,"status":407,"phases":3889,"primaryCompletion":1451,"completion":1452,"start":1453,"enrollment":374,"conditions":3890,"interventions":3891},[86],[1455,1456],[1458,1459,1460],{"trials":3893,"activeCount":97},[],{"trials":3895,"activeCount":97},[],{"trials":3897,"activeCount":97},[],{"trials":3899,"activeCount":97},[],{"intervention":3901,"totalTrials":93,"cells":3902},"Carbon Monoxide",{"EARLY_PHASE1":3903,"PHASE1":3905,"PHASE2":3916,"PHASE3":3918,"PHASE4":3920,"NA":3922},{"trials":3904,"activeCount":97},[],{"trials":3906,"activeCount":97},[3907],{"nctId":3908,"briefTitle":3909,"status":1174,"phases":3910,"primaryCompletion":3911,"completion":3912,"start":3913,"enrollment":31,"conditions":3914,"interventions":3915},"NCT03067701","Effects of Carbon Monoxide Breathing on Blood Vessel Function",[86],"2018-12-01","2019-03-01","2017-06-23",[1456],[3901],{"trials":3917,"activeCount":97},[],{"trials":3919,"activeCount":97},[],{"trials":3921,"activeCount":97},[],{"trials":3923,"activeCount":97},[],{"intervention":3925,"totalTrials":93,"cells":3926},"Allogeneic Human Cardiosphere-Derived Stem Cells",{"EARLY_PHASE1":3927,"PHASE1":3929,"PHASE2":3942,"PHASE3":3944,"PHASE4":3946,"NA":3948},{"trials":3928,"activeCount":97},[],{"trials":3930,"activeCount":97},[3931],{"nctId":3932,"briefTitle":3933,"status":1174,"phases":3934,"primaryCompletion":3935,"completion":3936,"start":3937,"enrollment":3938,"conditions":3939,"interventions":3941},"NCT03145298","ALlogeneic Cardiosphere-derived Stem Cells (CDCs) for Pulmonary Hypertension therApy",[86],"2023-01-31","2023-03-31","2017-10-01",26,[3940],"Pulmonary Arterial Hypertension (PAH)",[3925],{"trials":3943,"activeCount":97},[],{"trials":3945,"activeCount":97},[],{"trials":3947,"activeCount":97},[],{"trials":3949,"activeCount":97},[],{"intervention":3951,"totalTrials":93,"cells":3952},"Dendritic cell Vaccine",{"EARLY_PHASE1":3953,"PHASE1":3955,"PHASE2":3966,"PHASE3":3968,"PHASE4":3970,"NA":3972},{"trials":3954,"activeCount":97},[],{"trials":3956,"activeCount":97},[3957],{"nctId":3958,"briefTitle":3959,"status":1174,"phases":3960,"primaryCompletion":3961,"completion":3961,"start":3962,"enrollment":3963,"conditions":3964,"interventions":3965},"NCT00576446","Surgical Resection With Gliadel Wafer Followed by Dendritic Cells Vaccination for Malignant Glioma Patients",[86],"2012-05","2007-04",35,[3626],[3951],{"trials":3967,"activeCount":97},[],{"trials":3969,"activeCount":97},[],{"trials":3971,"activeCount":97},[],{"trials":3973,"activeCount":97},[],{"intervention":3975,"totalTrials":93,"cells":3976},"Stem cell (HPC) implantation",{"EARLY_PHASE1":3977,"PHASE1":3979,"PHASE2":3990,"PHASE3":3992,"PHASE4":3994,"NA":3996},{"trials":3978,"activeCount":97},[],{"trials":3980,"activeCount":97},[3981],{"nctId":3982,"briefTitle":3983,"status":1174,"phases":3984,"primaryCompletion":3985,"completion":3985,"start":3986,"enrollment":3987,"conditions":3988,"interventions":3989},"NCT02943850","CNS10-NPC-GDNF for the Treatment of ALS",[86],"2019-10-18","2017-04-01",18,[1084],[3975],{"trials":3991,"activeCount":97},[],{"trials":3993,"activeCount":97},[],{"trials":3995,"activeCount":97},[],{"trials":3997,"activeCount":97},[],{"intervention":3999,"totalTrials":93,"cells":4000},"Blinatumomab",{"EARLY_PHASE1":4001,"PHASE1":4003,"PHASE2":4017,"PHASE3":4019,"PHASE4":4021,"NA":4023},{"trials":4002,"activeCount":97},[],{"trials":4004,"activeCount":97},[4005],{"nctId":4006,"briefTitle":4007,"status":1174,"phases":4008,"primaryCompletion":4009,"completion":4010,"start":4011,"enrollment":3647,"conditions":4012,"interventions":4016},"NCT03751709","Blinatumomab Plus HLA-Mismatched Cellular Therapy for Relapsed\u002FRefractory CD19+ ALL",[86],"2023-03-27","2024-11-12","2020-02-14",[4013,4014,4015],"B-Cell Acute Lymphoblastic Leukaemia","ALL, Adult","B-ALL",[3999],{"trials":4018,"activeCount":97},[],{"trials":4020,"activeCount":97},[],{"trials":4022,"activeCount":97},[],{"trials":4024,"activeCount":97},[],{"intervention":4026,"totalTrials":93,"cells":4027},"Sodium Nitrate",{"EARLY_PHASE1":4028,"PHASE1":4030,"PHASE2":4039,"PHASE3":4041,"PHASE4":4043,"NA":4045},{"trials":4029,"activeCount":97},[],{"trials":4031,"activeCount":97},[4032],{"nctId":4033,"briefTitle":4034,"status":1174,"phases":4035,"primaryCompletion":4036,"completion":4036,"start":1406,"enrollment":2559,"conditions":4037,"interventions":4038},"NCT02434627","Sodium Nitrate for Muscular Dystrophy",[86],"2018-04",[1475],[4026],{"trials":4040,"activeCount":97},[],{"trials":4042,"activeCount":97},[],{"trials":4044,"activeCount":97},[],{"trials":4046,"activeCount":97},[],{"intervention":4048,"totalTrials":93,"cells":4049},"Mobile Clinic",{"EARLY_PHASE1":4050,"PHASE1":4064,"PHASE2":4066,"PHASE3":4068,"PHASE4":4070,"NA":4072},{"trials":4051,"activeCount":97},[4052],{"nctId":4053,"briefTitle":4054,"status":264,"phases":4055,"primaryCompletion":4056,"completion":4057,"start":4058,"enrollment":237,"conditions":4059,"interventions":4063},"NCT03953911","Increasing HPV Vaccination Rates Via Educational Interventions in Schools Located Within Cedars-Sinai Catchment Areas",[85],"2020-05-27","2020-06-30","2019-05-28",[4060,4061,4062],"Human Papilloma Virus","HPV Vaccination","Health Education",[4048],{"trials":4065,"activeCount":97},[],{"trials":4067,"activeCount":97},[],{"trials":4069,"activeCount":97},[],{"trials":4071,"activeCount":97},[],{"trials":4073,"activeCount":97},[],{"intervention":417,"totalTrials":93,"cells":4075},{"EARLY_PHASE1":4076,"PHASE1":4082,"PHASE2":4084,"PHASE3":4086,"PHASE4":4088,"NA":4090},{"trials":4077,"activeCount":97},[4078],{"nctId":405,"briefTitle":406,"status":407,"phases":4079,"primaryCompletion":409,"completion":410,"start":411,"enrollment":34,"conditions":4080,"interventions":4081},[85],[413,414,415],[417,400],{"trials":4083,"activeCount":97},[],{"trials":4085,"activeCount":97},[],{"trials":4087,"activeCount":97},[],{"trials":4089,"activeCount":97},[],{"trials":4091,"activeCount":97},[],{"intervention":4093,"totalTrials":93,"cells":4094},"Tadalafil 20 MG",{"EARLY_PHASE1":4095,"PHASE1":4105,"PHASE2":4107,"PHASE3":4109,"PHASE4":4111,"NA":4113},{"trials":4096,"activeCount":97},[4097],{"nctId":4098,"briefTitle":4099,"status":407,"phases":4100,"primaryCompletion":2138,"completion":2138,"start":4101,"enrollment":3063,"conditions":4102,"interventions":4104},"NCT02653833","The Study of Skeletal Muscle Blood Flow in Becker Muscular Dystrophy",[85],"2017-11-01",[4103],"Muscular Dystrophy",[4093],{"trials":4106,"activeCount":97},[],{"trials":4108,"activeCount":97},[],{"trials":4110,"activeCount":97},[],{"trials":4112,"activeCount":97},[],{"trials":4114,"activeCount":97},[],{"intervention":4116,"totalTrials":93,"cells":4117},"ezetimibe 10mg-simvastatin 40mg",{"EARLY_PHASE1":4118,"PHASE1":4128,"PHASE2":4130,"PHASE3":4132,"PHASE4":4134,"NA":4136},{"trials":4119,"activeCount":97},[4120],{"nctId":4121,"briefTitle":4122,"status":1174,"phases":4123,"primaryCompletion":4124,"completion":4124,"start":4125,"enrollment":1494,"conditions":4126,"interventions":4127},"NCT02534376","Cellular Effect of Cholesterol-Lowering Prior to Prostate Removal",[85],"2019-02-28","2015-09",[26],[4116],{"trials":4129,"activeCount":97},[],{"trials":4131,"activeCount":97},[],{"trials":4133,"activeCount":97},[],{"trials":4135,"activeCount":97},[],{"trials":4137,"activeCount":97},[],{"intervention":1444,"totalTrials":93,"cells":4139},{"EARLY_PHASE1":4140,"PHASE1":4146,"PHASE2":4148,"PHASE3":4150,"PHASE4":4152,"NA":4154},{"trials":4141,"activeCount":97},[4142],{"nctId":1435,"briefTitle":1436,"status":1174,"phases":4143,"primaryCompletion":1438,"completion":1438,"start":1439,"enrollment":1440,"conditions":4144,"interventions":4145},[85],[1442],[1430,1444],{"trials":4147,"activeCount":97},[],{"trials":4149,"activeCount":97},[],{"trials":4151,"activeCount":97},[],{"trials":4153,"activeCount":97},[],{"trials":4155,"activeCount":97},[],{"intervention":2684,"totalTrials":93,"cells":4157},{"EARLY_PHASE1":4158,"PHASE1":4164,"PHASE2":4166,"PHASE3":4168,"PHASE4":4170,"NA":4172},{"trials":4159,"activeCount":97},[4160],{"nctId":2676,"briefTitle":2677,"status":1174,"phases":4161,"primaryCompletion":2679,"completion":2679,"start":2680,"enrollment":1673,"conditions":4162,"interventions":4163},[85],[2682,304],[2684,2671],{"trials":4165,"activeCount":97},[],{"trials":4167,"activeCount":97},[],{"trials":4169,"activeCount":97},[],{"trials":4171,"activeCount":97},[],{"trials":4173,"activeCount":97},[],{"intervention":3439,"totalTrials":93,"cells":4175},{"EARLY_PHASE1":4176,"PHASE1":4191,"PHASE2":4193,"PHASE3":4195,"PHASE4":4197,"NA":4199},{"trials":4177,"activeCount":97},[4178],{"nctId":4179,"briefTitle":4180,"status":1174,"phases":4181,"primaryCompletion":4182,"completion":4182,"start":4183,"enrollment":4184,"conditions":4185,"interventions":4188},"NCT01927640","Dexmedetomidine for Reversal of Cocaine's Effects on the Heart",[85],"2014-01-15","2013-02-01",115,[4186,4187],"Chest Pain","Acute Coronary Syndrome",[3439,4189,4190],"Normal Saline","Intranasal cocaine",{"trials":4192,"activeCount":97},[],{"trials":4194,"activeCount":97},[],{"trials":4196,"activeCount":97},[],{"trials":4198,"activeCount":97},[],{"trials":4200,"activeCount":97},[],{"intervention":4189,"totalTrials":93,"cells":4202},{"EARLY_PHASE1":4203,"PHASE1":4209,"PHASE2":4211,"PHASE3":4213,"PHASE4":4215,"NA":4217},{"trials":4204,"activeCount":97},[4205],{"nctId":4179,"briefTitle":4180,"status":1174,"phases":4206,"primaryCompletion":4182,"completion":4182,"start":4183,"enrollment":4184,"conditions":4207,"interventions":4208},[85],[4186,4187],[3439,4189,4190],{"trials":4210,"activeCount":97},[],{"trials":4212,"activeCount":97},[],{"trials":4214,"activeCount":97},[],{"trials":4216,"activeCount":97},[],{"trials":4218,"activeCount":97},[],{"intervention":4190,"totalTrials":93,"cells":4220},{"EARLY_PHASE1":4221,"PHASE1":4227,"PHASE2":4229,"PHASE3":4231,"PHASE4":4233,"NA":4235},{"trials":4222,"activeCount":97},[4223],{"nctId":4179,"briefTitle":4180,"status":1174,"phases":4224,"primaryCompletion":4182,"completion":4182,"start":4183,"enrollment":4184,"conditions":4225,"interventions":4226},[85],[4186,4187],[3439,4189,4190],{"trials":4228,"activeCount":97},[],{"trials":4230,"activeCount":97},[],{"trials":4232,"activeCount":97},[],{"trials":4234,"activeCount":97},[],{"trials":4236,"activeCount":97},[],{"intervention":4238,"totalTrials":332,"cells":4239},"Pegvisomant",{"EARLY_PHASE1":4240,"PHASE1":4242,"PHASE2":4244,"PHASE3":4246,"PHASE4":4248,"NA":4250},{"trials":4241,"activeCount":97},[],{"trials":4243,"activeCount":97},[],{"trials":4245,"activeCount":97},[],{"trials":4247,"activeCount":97},[],{"trials":4249,"activeCount":97},[],{"trials":4251,"activeCount":97},[4252,4263],{"nctId":4253,"briefTitle":4254,"status":407,"phases":4255,"primaryCompletion":4256,"completion":4256,"start":4257,"enrollment":4258,"conditions":4259,"interventions":4260},"NCT01538966","Acromegaly Combination Treatment Study",[90],"2022-05-20","2012-03-29",76,[30],[4238,4261,4262],"Octreotide LAR","Lanreotide",{"nctId":4264,"briefTitle":4265,"status":1174,"phases":4266,"primaryCompletion":3670,"completion":4267,"start":391,"enrollment":4268,"conditions":4269,"interventions":4270},"NCT01261000","Tissue Biomarker for Pegvisomant Action",[90],"2013-12",8,[30],[4238],{"intervention":1426,"totalTrials":332,"cells":4272},{"EARLY_PHASE1":4273,"PHASE1":4275,"PHASE2":4277,"PHASE3":4279,"PHASE4":4281,"NA":4287},{"trials":4274,"activeCount":97},[],{"trials":4276,"activeCount":97},[],{"trials":4278,"activeCount":97},[],{"trials":4280,"activeCount":97},[],{"trials":4282,"activeCount":97},[4283],{"nctId":1417,"briefTitle":1418,"status":1174,"phases":4284,"primaryCompletion":1420,"completion":1421,"start":1422,"enrollment":1423,"conditions":4285,"interventions":4286},[89],[281],[1362,1426,1353],{"trials":4288,"activeCount":97},[4289],{"nctId":4290,"briefTitle":4291,"status":1174,"phases":4292,"primaryCompletion":1406,"completion":4293,"start":1378,"enrollment":2442,"conditions":4294,"interventions":4296},"NCT02168309","Oral Nifedipine Versus Oral Labetalol",[90],"2016-05",[4295],"Severe Postpartum Hypertension",[1426,4297],"Nifedipine",{"intervention":4299,"totalTrials":332,"cells":4300},"Ranolazine",{"EARLY_PHASE1":4301,"PHASE1":4303,"PHASE2":4305,"PHASE3":4314,"PHASE4":4316,"NA":4318},{"trials":4302,"activeCount":97},[],{"trials":4304,"activeCount":97},[],{"trials":4306,"activeCount":97},[4307],{"nctId":4308,"briefTitle":4309,"status":1174,"phases":4310,"primaryCompletion":1696,"completion":1696,"start":3962,"enrollment":268,"conditions":4311,"interventions":4313},"NCT00570089","Microvascular Coronary Disease In Women: Impact Of Ranolazine",[87],[4312],"Myocardial Ischemia",[4299],{"trials":4315,"activeCount":97},[],{"trials":4317,"activeCount":97},[],{"trials":4319,"activeCount":97},[4320],{"nctId":4321,"briefTitle":4322,"status":1174,"phases":4323,"primaryCompletion":4324,"completion":4324,"start":1439,"enrollment":4325,"conditions":4326,"interventions":4328},"NCT01342029","Treatment With Ranolazine in Microvascular Coronary Dysfunction (MCD): Impact on Angina Myocardial Ischemia",[90],"2016-12",142,[4327],"Microvascular Coronary Dysfunction (MCD)",[4299],{"intervention":4330,"totalTrials":93,"cells":4331},"Blood test",{"EARLY_PHASE1":4332,"PHASE1":4334,"PHASE2":4336,"PHASE3":4338,"PHASE4":4340,"NA":4342},{"trials":4333,"activeCount":97},[],{"trials":4335,"activeCount":97},[],{"trials":4337,"activeCount":97},[],{"trials":4339,"activeCount":97},[],{"trials":4341,"activeCount":97},[],{"trials":4343,"activeCount":97},[4344],{"nctId":4345,"briefTitle":4346,"status":1174,"phases":4347,"primaryCompletion":4348,"completion":4348,"start":4349,"enrollment":1423,"conditions":4350,"interventions":4351},"NCT00572858","Estrogen Deficiency and Cardiovascular Disease in Premenopausal Women",[],"2020-10","2005-01",[3251],[4330],{"intervention":4353,"totalTrials":93,"cells":4354},"fulvestrant",{"EARLY_PHASE1":4355,"PHASE1":4357,"PHASE2":4359,"PHASE3":4361,"PHASE4":4363,"NA":4365},{"trials":4356,"activeCount":97},[],{"trials":4358,"activeCount":97},[],{"trials":4360,"activeCount":97},[],{"trials":4362,"activeCount":97},[],{"trials":4364,"activeCount":97},[],{"trials":4366,"activeCount":97},[4367],{"nctId":4368,"briefTitle":4369,"status":264,"phases":4370,"start":4371,"enrollment":111,"conditions":4372,"interventions":4373},"NCT00126464","Fulvestrant or Tamoxifen in Treating Postmenopausal Women Who Are Undergoing Surgery for Ductal Carcinoma in Situ of the Breast",[90],"2004-11",[15],[4353,4374],"tamoxifen citrate",{"intervention":4374,"totalTrials":93,"cells":4376},{"EARLY_PHASE1":4377,"PHASE1":4379,"PHASE2":4381,"PHASE3":4383,"PHASE4":4385,"NA":4387},{"trials":4378,"activeCount":97},[],{"trials":4380,"activeCount":97},[],{"trials":4382,"activeCount":97},[],{"trials":4384,"activeCount":97},[],{"trials":4386,"activeCount":97},[],{"trials":4388,"activeCount":97},[4389],{"nctId":4368,"briefTitle":4369,"status":264,"phases":4390,"start":4371,"enrollment":111,"conditions":4391,"interventions":4392},[90],[15],[4353,4374],{"intervention":4394,"totalTrials":93,"cells":4395},"Prazosin given 6 hours prior to catheter removal in the 24 hour group",{"EARLY_PHASE1":4396,"PHASE1":4398,"PHASE2":4400,"PHASE3":4402,"PHASE4":4404,"NA":4406},{"trials":4397,"activeCount":97},[],{"trials":4399,"activeCount":97},[],{"trials":4401,"activeCount":97},[],{"trials":4403,"activeCount":97},[],{"trials":4405,"activeCount":97},[],{"trials":4407,"activeCount":97},[4408],{"nctId":4409,"briefTitle":4410,"status":1174,"phases":4411,"primaryCompletion":4412,"completion":4412,"start":4413,"enrollment":4325,"conditions":4414,"interventions":4416},"NCT01923129","Optimal Duration of Indwelling Urinary Catheter Following Pelvic Surgery",[90],"2017-11-22","2012-11-30",[4415],"Urinary Retention",[4394],{"intervention":4418,"totalTrials":93,"cells":4419},"23-valent polysaccharide pneumococcal vaccine",{"EARLY_PHASE1":4420,"PHASE1":4422,"PHASE2":4424,"PHASE3":4426,"PHASE4":4428,"NA":4430},{"trials":4421,"activeCount":97},[],{"trials":4423,"activeCount":97},[],{"trials":4425,"activeCount":97},[],{"trials":4427,"activeCount":97},[],{"trials":4429,"activeCount":97},[],{"trials":4431,"activeCount":97},[4432],{"nctId":4433,"briefTitle":4434,"status":1174,"phases":4435,"primaryCompletion":4436,"completion":4436,"start":4437,"enrollment":4438,"conditions":4439,"interventions":4442},"NCT00829595","Pneumococcal Vaccination in Patients With Inflammatory Bowel Disease",[90],"2007-12","2005-05",69,[4440,694,4441],"Inflammatory Bowel Disease","Ulcerative Colitis",[4418],{"intervention":4261,"totalTrials":93,"cells":4444},{"EARLY_PHASE1":4445,"PHASE1":4447,"PHASE2":4449,"PHASE3":4451,"PHASE4":4453,"NA":4455},{"trials":4446,"activeCount":97},[],{"trials":4448,"activeCount":97},[],{"trials":4450,"activeCount":97},[],{"trials":4452,"activeCount":97},[],{"trials":4454,"activeCount":97},[],{"trials":4456,"activeCount":97},[4457],{"nctId":4253,"briefTitle":4254,"status":407,"phases":4458,"primaryCompletion":4256,"completion":4256,"start":4257,"enrollment":4258,"conditions":4459,"interventions":4460},[90],[30],[4238,4261,4262],{"intervention":4262,"totalTrials":93,"cells":4462},{"EARLY_PHASE1":4463,"PHASE1":4465,"PHASE2":4467,"PHASE3":4469,"PHASE4":4471,"NA":4473},{"trials":4464,"activeCount":97},[],{"trials":4466,"activeCount":97},[],{"trials":4468,"activeCount":97},[],{"trials":4470,"activeCount":97},[],{"trials":4472,"activeCount":97},[],{"trials":4474,"activeCount":97},[4475],{"nctId":4253,"briefTitle":4254,"status":407,"phases":4476,"primaryCompletion":4256,"completion":4256,"start":4257,"enrollment":4258,"conditions":4477,"interventions":4478},[90],[30],[4238,4261,4262],{"intervention":4297,"totalTrials":93,"cells":4480},{"EARLY_PHASE1":4481,"PHASE1":4483,"PHASE2":4485,"PHASE3":4487,"PHASE4":4489,"NA":4491},{"trials":4482,"activeCount":97},[],{"trials":4484,"activeCount":97},[],{"trials":4486,"activeCount":97},[],{"trials":4488,"activeCount":97},[],{"trials":4490,"activeCount":97},[],{"trials":4492,"activeCount":97},[4493],{"nctId":4290,"briefTitle":4291,"status":1174,"phases":4494,"primaryCompletion":1406,"completion":4293,"start":1378,"enrollment":2442,"conditions":4495,"interventions":4496},[90],[4295],[1426,4297],{"intervention":4498,"totalTrials":93,"cells":4499},"1\u002F10 NA\u002FEE",{"EARLY_PHASE1":4500,"PHASE1":4502,"PHASE2":4504,"PHASE3":4506,"PHASE4":4508,"NA":4510},{"trials":4501,"activeCount":97},[],{"trials":4503,"activeCount":97},[],{"trials":4505,"activeCount":97},[],{"trials":4507,"activeCount":97},[],{"trials":4509,"activeCount":97},[],{"trials":4511,"activeCount":97},[4512],{"nctId":4513,"briefTitle":4514,"status":1174,"phases":4515,"primaryCompletion":1177,"completion":4516,"start":4517,"enrollment":2417,"conditions":4518,"interventions":4519},"NCT00600106","Data Analyses for Ancillary WISE Femhrt Hormone Replacement Study",[90],"2010-03","1999-12",[4312],[4498],{"intervention":1261,"totalTrials":93,"cells":4521},{"EARLY_PHASE1":4522,"PHASE1":4524,"PHASE2":4526,"PHASE3":4528,"PHASE4":4530,"NA":4532},{"trials":4523,"activeCount":97},[],{"trials":4525,"activeCount":97},[],{"trials":4527,"activeCount":97},[],{"trials":4529,"activeCount":97},[],{"trials":4531,"activeCount":97},[],{"trials":4533,"activeCount":97},[4534],{"nctId":1253,"briefTitle":1254,"status":264,"phases":4535,"primaryCompletion":1256,"completion":1256,"start":1257,"enrollment":302,"conditions":4536,"interventions":4537},[],[18,1259],[45,1261],{"intervention":4539,"totalTrials":93,"cells":4540},"US TAP Bupivacaine\u002FEpinephrine",{"EARLY_PHASE1":4541,"PHASE1":4543,"PHASE2":4545,"PHASE3":4547,"PHASE4":4549,"NA":4551},{"trials":4542,"activeCount":97},[],{"trials":4544,"activeCount":97},[],{"trials":4546,"activeCount":97},[],{"trials":4548,"activeCount":97},[],{"trials":4550,"activeCount":97},[],{"trials":4552,"activeCount":97},[4553],{"nctId":4554,"briefTitle":4555,"status":1174,"phases":4556,"primaryCompletion":4557,"completion":4557,"start":4558,"enrollment":4559,"conditions":4560,"interventions":4562},"NCT02538679","A Comparison of Ultrasound Guided Transversus Abdominis Plane Nerve Block Techniques",[90],"2017-04-30","2015-08-07",127,[4561,4440,113],"Crohn's Disease",[4539,4563],"Lap TAP Bupivacaine\u002FEpinephrine",{"intervention":4563,"totalTrials":93,"cells":4565},{"EARLY_PHASE1":4566,"PHASE1":4568,"PHASE2":4570,"PHASE3":4572,"PHASE4":4574,"NA":4576},{"trials":4567,"activeCount":97},[],{"trials":4569,"activeCount":97},[],{"trials":4571,"activeCount":97},[],{"trials":4573,"activeCount":97},[],{"trials":4575,"activeCount":97},[],{"trials":4577,"activeCount":97},[4578],{"nctId":4554,"briefTitle":4555,"status":1174,"phases":4579,"primaryCompletion":4557,"completion":4557,"start":4558,"enrollment":4559,"conditions":4580,"interventions":4581},[90],[4561,4440,113],[4539,4563],{"intervention":4583,"totalTrials":93,"cells":4584},"Standard pain management regimen",{"EARLY_PHASE1":4585,"PHASE1":4587,"PHASE2":4589,"PHASE3":4591,"PHASE4":4593,"NA":4595},{"trials":4586,"activeCount":97},[],{"trials":4588,"activeCount":97},[],{"trials":4590,"activeCount":97},[],{"trials":4592,"activeCount":97},[],{"trials":4594,"activeCount":97},[],{"trials":4596,"activeCount":97},[4597],{"nctId":4598,"briefTitle":4599,"status":1174,"phases":4600,"primaryCompletion":4601,"completion":4601,"start":4602,"enrollment":3407,"conditions":4603,"interventions":4605},"NCT05868369","The Effectiveness of Immersive Virtual Reality as a Pain Control Modality After Hip Arthroscopy",[90],"2025-04-25","2023-11-01",[4604],"Hip Pain Chronic",[4583],{"intervention":4607,"totalTrials":93,"cells":4608},"Marcaine",{"EARLY_PHASE1":4609,"PHASE1":4611,"PHASE2":4613,"PHASE3":4615,"PHASE4":4617,"NA":4619},{"trials":4610,"activeCount":97},[],{"trials":4612,"activeCount":97},[],{"trials":4614,"activeCount":97},[],{"trials":4616,"activeCount":97},[],{"trials":4618,"activeCount":97},[],{"trials":4620,"activeCount":97},[4621],{"nctId":4622,"briefTitle":4623,"status":407,"phases":4624,"primaryCompletion":4625,"completion":4625,"start":3248,"enrollment":4626,"conditions":4627,"interventions":4628},"NCT02826551","Pain Outcomes After Anterior Cruciate Ligament Reconstruction With Posterior Capsular Marcaine Injection",[90],"2017-05-10",23,[270],[4607,4629],"Percocet",{"intervention":4629,"totalTrials":93,"cells":4631},{"EARLY_PHASE1":4632,"PHASE1":4634,"PHASE2":4636,"PHASE3":4638,"PHASE4":4640,"NA":4642},{"trials":4633,"activeCount":97},[],{"trials":4635,"activeCount":97},[],{"trials":4637,"activeCount":97},[],{"trials":4639,"activeCount":97},[],{"trials":4641,"activeCount":97},[],{"trials":4643,"activeCount":97},[4644],{"nctId":4622,"briefTitle":4623,"status":407,"phases":4645,"primaryCompletion":4625,"completion":4625,"start":3248,"enrollment":4626,"conditions":4646,"interventions":4647},[90],[270],[4607,4629],{"intervention":4649,"totalTrials":93,"cells":4650},"Lexapro",{"EARLY_PHASE1":4651,"PHASE1":4653,"PHASE2":4655,"PHASE3":4657,"PHASE4":4659,"NA":4661},{"trials":4652,"activeCount":97},[],{"trials":4654,"activeCount":97},[],{"trials":4656,"activeCount":97},[],{"trials":4658,"activeCount":97},[],{"trials":4660,"activeCount":97},[],{"trials":4662,"activeCount":97},[4663],{"nctId":4664,"briefTitle":4665,"status":407,"phases":4666,"primaryCompletion":4667,"completion":4667,"start":1697,"enrollment":2840,"conditions":4668,"interventions":4669},"NCT00643162","Combination Lexapro and Massage for Treatment of Depression in Older Adults",[90],"2010-02",[21],[4649],{"intervention":272,"totalTrials":93,"cells":4671},{"EARLY_PHASE1":4672,"PHASE1":4674,"PHASE2":4676,"PHASE3":4678,"PHASE4":4680,"NA":4682},{"trials":4673,"activeCount":97},[],{"trials":4675,"activeCount":97},[],{"trials":4677,"activeCount":97},[],{"trials":4679,"activeCount":97},[],{"trials":4681,"activeCount":97},[],{"trials":4683,"activeCount":97},[4684],{"nctId":262,"briefTitle":263,"status":264,"phases":4685,"primaryCompletion":266,"completion":266,"start":267,"enrollment":268,"conditions":4686,"interventions":4687},[90],[33,270,24],[272,236],{"intervention":4689,"totalTrials":93,"cells":4690},"Lubiprostone",{"EARLY_PHASE1":4691,"PHASE1":4693,"PHASE2":4695,"PHASE3":4697,"PHASE4":4699,"NA":4701},{"trials":4692,"activeCount":97},[],{"trials":4694,"activeCount":97},[],{"trials":4696,"activeCount":97},[],{"trials":4698,"activeCount":97},[],{"trials":4700,"activeCount":97},[],{"trials":4702,"activeCount":97},[4703],{"nctId":4704,"briefTitle":4705,"status":1174,"phases":4706,"primaryCompletion":4707,"completion":4707,"start":4516,"enrollment":1332,"conditions":4708,"interventions":4710},"NCT01085643","Effect of Lubiprostone on Small Bowel Contractions in Female Patients With Constipation Irritable Bowel Syndrome (C-IBS)",[90],"2010-12",[4709],"Constipation-predominant Irritable Bowel Syndrome",[4689],{"intervention":4712,"totalTrials":93,"cells":4713},"indocyanine green",{"EARLY_PHASE1":4714,"PHASE1":4716,"PHASE2":4718,"PHASE3":4720,"PHASE4":4722,"NA":4724},{"trials":4715,"activeCount":97},[],{"trials":4717,"activeCount":97},[],{"trials":4719,"activeCount":97},[],{"trials":4721,"activeCount":97},[],{"trials":4723,"activeCount":97},[],{"trials":4725,"activeCount":97},[4726],{"nctId":4727,"briefTitle":4728,"status":1174,"phases":4729,"primaryCompletion":4730,"completion":4730,"start":4731,"enrollment":34,"conditions":4732,"interventions":4736},"NCT03888014","Intraoperative Fluorescence With Augmented Reality",[],"2021-06-01","2019-07-01",[4733,3698,4734,4735],"Vascular; Lesion, Central Nervous System","Cerebral Aneurysm","Cerebral AVM",[4712],{"intervention":4738,"totalTrials":93,"cells":4739},"Hydrocortisone High Dose",{"EARLY_PHASE1":4740,"PHASE1":4742,"PHASE2":4744,"PHASE3":4746,"PHASE4":4748,"NA":4750},{"trials":4741,"activeCount":97},[],{"trials":4743,"activeCount":97},[],{"trials":4745,"activeCount":97},[],{"trials":4747,"activeCount":97},[],{"trials":4749,"activeCount":97},[],{"trials":4751,"activeCount":97},[4752],{"nctId":4753,"briefTitle":4754,"status":1174,"phases":4755,"primaryCompletion":2680,"completion":2680,"start":4756,"enrollment":4757,"conditions":4758,"interventions":4763},"NCT01559675","Trial Comparing Low Dose and High Dose Steroids in Patients Undergoing Colorectal Surgery",[90],"2010-09",121,[4759,4760,4761,4762],"Orthostatic Hypotension","Hemodynamic Instability","Fever","Hypothermia",[4738,4764],"Hydrocortisone Low Dose",{"intervention":4764,"totalTrials":93,"cells":4766},{"EARLY_PHASE1":4767,"PHASE1":4769,"PHASE2":4771,"PHASE3":4773,"PHASE4":4775,"NA":4777},{"trials":4768,"activeCount":97},[],{"trials":4770,"activeCount":97},[],{"trials":4772,"activeCount":97},[],{"trials":4774,"activeCount":97},[],{"trials":4776,"activeCount":97},[],{"trials":4778,"activeCount":97},[4779],{"nctId":4753,"briefTitle":4754,"status":1174,"phases":4780,"primaryCompletion":2680,"completion":2680,"start":4756,"enrollment":4757,"conditions":4781,"interventions":4782},[90],[4759,4760,4761,4762],[4738,4764],{"intervention":4784,"totalTrials":93,"cells":4785},"testerone gel",{"EARLY_PHASE1":4786,"PHASE1":4788,"PHASE2":4790,"PHASE3":4792,"PHASE4":4794,"NA":4796},{"trials":4787,"activeCount":97},[],{"trials":4789,"activeCount":97},[],{"trials":4791,"activeCount":97},[],{"trials":4793,"activeCount":97},[],{"trials":4795,"activeCount":97},[],{"trials":4797,"activeCount":97},[4798],{"nctId":4799,"briefTitle":4800,"status":387,"phases":4801,"primaryCompletion":4802,"completion":1471,"start":4803,"enrollment":97,"conditions":4804,"interventions":4806},"NCT01377103","Testosterone Therapy in Heart Failure",[90],"2012-10","2011-07",[2308,4805],"Hypogonadism",[4784]]